tag:blogger.com,1999:blog-107439432024-02-22T03:16:50.484+13:00Smooth SailingOpinions and thoughts on technology, how we work and keeping it simple.
From Spiral and friends. Hope you enjoy the read.Anonymoushttp://www.blogger.com/profile/04133048815467794104noreply@blogger.comBlogger238125tag:blogger.com,1999:blog-10743943.post-44556593428707299242023-12-14T08:12:00.002+13:002023-12-14T08:12:10.264+13:00Perspective Changed, Problem Solved - Meet Cain Harland<div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiMocvb8zM94picFNtaqfQlWi-cEagzxSMINpQOky5vU3feEykmq1oAJHRAvJEPzPGIGCd9AjuBdMS_-EoWwEnro2lQ7xs9c9W9kmX41lewfJ8XmyYVQNllT11ruHys1hgz8N9RpxzUQJRgMB1XLHYvbnLbUmKbq4lUl9Io15exD0sTrNfg6m5t/s1500/CAIN.jpg" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" data-original-height="995" data-original-width="1500" height="212" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiMocvb8zM94picFNtaqfQlWi-cEagzxSMINpQOky5vU3feEykmq1oAJHRAvJEPzPGIGCd9AjuBdMS_-EoWwEnro2lQ7xs9c9W9kmX41lewfJ8XmyYVQNllT11ruHys1hgz8N9RpxzUQJRgMB1XLHYvbnLbUmKbq4lUl9Io15exD0sTrNfg6m5t/s320/CAIN.jpg" width="320" /></a></div><span style="color: #374151; font-family: Söhne, ui-sans-serif, system-ui, -apple-system, "Segoe UI", Roboto, Ubuntu, Cantarell, "Noto Sans", sans-serif, "Helvetica Neue", Arial, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Noto Color Emoji"; font-size: 16px; white-space-collapse: preserve;">Say hello to Cain Harland – Spiral's Development Lead and a bit of an unsung hero. Cain's story isn't your typical tech journey. It starts in the scenic Hawkes Bay and winds its way through a mix of personal training, a flair for web design, and finally, a deep dive into software development.</span><div><span style="color: #374151; font-family: Söhne, ui-sans-serif, system-ui, -apple-system, "Segoe UI", Roboto, Ubuntu, Cantarell, "Noto Sans", sans-serif, "Helvetica Neue", Arial, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Noto Color Emoji"; font-size: 16px; white-space-collapse: preserve;"><br /></span></div><div><span style="color: #374151; font-family: Söhne, ui-sans-serif, system-ui, -apple-system, "Segoe UI", Roboto, Ubuntu, Cantarell, "Noto Sans", sans-serif, "Helvetica Neue", Arial, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Noto Color Emoji"; font-size: 16px; white-space-collapse: preserve;">At Spiral, he's the brains behind the Spinnaker software, quietly revolutionising how we approach clinical trials. Cain's days are a blend of coding, problem-solving, and big-picture thinking, all done with the humble goal of making a real difference in medical research. </span></div><div><span style="color: #374151; font-family: Söhne, ui-sans-serif, system-ui, -apple-system, "Segoe UI", Roboto, Ubuntu, Cantarell, "Noto Sans", sans-serif, "Helvetica Neue", Arial, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Noto Color Emoji"; font-size: 16px; white-space-collapse: preserve;"><br /></span></div><div><span style="color: #374151; font-family: Söhne, ui-sans-serif, system-ui, -apple-system, "Segoe UI", Roboto, Ubuntu, Cantarell, "Noto Sans", sans-serif, "Helvetica Neue", Arial, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Noto Color Emoji"; font-size: 16px; white-space-collapse: preserve;">From his early days in Wellington to working remotely from the most unexpected places, join us as we explore the life of a man who's as down-to-earth as he is innovative.
<a href="https://spiral.co.nz/resources/meet-cain">Read about Cain on our blog</a></span><br /><h1 class="entry-title entry-title--large p-name preFade fadeIn" data-content-field="title" itemprop="headline" style="background-color: white; color: var(--tweak-blog-item-title-color); font-family: var(--blog-item-title-font-font-family); font-size: calc((var(--blog-item-title-font-font-size-value) - 1) * 1.2vw + 1rem); font-weight: var(--blog-item-title-font-font-weight); line-height: var(--blog-item-title-font-line-height); margin: 0px; opacity: 1 !important; transition-delay: 0.166154s; transition-duration: 0.9s; transition-property: opacity; transition-timing-function: ease;"><br /></h1></div>Audreyhttp://www.blogger.com/profile/10419461620219923125noreply@blogger.com0tag:blogger.com,1999:blog-10743943.post-18247394650687686142023-03-13T12:55:00.039+13:002023-03-13T13:53:09.029+13:00Better Health Outcomes Together - The PANORAMIC Case Study with Lead Statistician Ly-Mee Yu<div><span style="font-family: arial;"><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEghmeNbhGdUmb_Q7xWNgnVJQv-jCRaGwWYxYF_TaZOz480V_2l-o4nnhCHlD8jlz0ossa2sGT8fFeyxO9NFKwMsjqKw5wNoUG7UOnKKK4R8gqaKzYteavF2gZM1p9Cn86eVgG5A3aw0zf1QypLNkBbtmPnJ-3JC5u4FDaBkQXA9EHt28ZAYhw/s1200/Carousel%202.%20last%20page.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="1200" data-original-width="1200" height="320" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEghmeNbhGdUmb_Q7xWNgnVJQv-jCRaGwWYxYF_TaZOz480V_2l-o4nnhCHlD8jlz0ossa2sGT8fFeyxO9NFKwMsjqKw5wNoUG7UOnKKK4R8gqaKzYteavF2gZM1p9Cn86eVgG5A3aw0zf1QypLNkBbtmPnJ-3JC5u4FDaBkQXA9EHt28ZAYhw/s320/Carousel%202.%20last%20page.png" width="320" /></a></div><br /><span color="var(--tweak-blog-item-title-color)" style="background-color: white; font-size: calc(1.2vw + 1rem); letter-spacing: 0em;"><br /></span></span></div><div class="blog-item-content-wrapper" id="yui_3_17_2_1_1678665215504_73" style="background-color: white;"><div class="blog-item-content e-content" id="yui_3_17_2_1_1678665215504_72" style="margin: 0px 0px 3vw;"><div class="sqs-layout sqs-grid-12 columns-12" data-layout-label="Post Body" data-type="item" id="item-63e9ed155fb90602c9062c20"><div class="row sqs-row" id="yui_3_17_2_1_1678665215504_71" style="margin-left: -17px; margin-right: -17px; width: auto;"><div class="col sqs-col-12 span-12" id="yui_3_17_2_1_1678665215504_70" style="float: left; padding-right: 0px; width: 898px;"><div class="sqs-block html-block sqs-block-html" data-block-type="2" id="block-1b31e7ae8024af14c621" style="clear: none; height: auto; padding: 0px 17px 17px; position: relative;"><div class="sqs-block-content" style="outline: none;"><p style="margin: 0px 0px 1rem; overflow-wrap: break-word;"><span style="font-size: 16px; font-weight: 700; white-space: pre-wrap;"><span style="font-family: inherit;">‘One of the purposes behind the trial is discovering which antivirals are effective in keeping people away from the hospitals as much as they can and alleviating the burden on the healthcare system.'</span></span></p><p style="margin: 0px 0px 1rem; overflow-wrap: break-word;"><span style="color: #333333; font-family: inherit;"><span style="white-space: pre-wrap;">The PANORAMIC trial is an adaptive platform trial aimed at finding early treatments for COVID-19 by evaluating new antiviral treatments in the community, reducing hospital admissions and easing the burden on the healthcare system. </span></span></p><p style="margin: 0px 0px 1rem; overflow-wrap: break-word;"><span style="color: #333333; font-family: inherit;"><span style="white-space: pre-wrap;">The trial has recruited over 26,000 people across 65 sites using various recruitment strategies. Spiral’s Spinnaker platform has helped streamline the trial’s software requirements since October 2021. Recent results have shown that Molnupiravir does not reduce hospitalizations or deaths in higher-risk, vaccinated adults with COVID-19. </span></span></p><p style="margin: 0px 0px 1rem; overflow-wrap: break-word;"><span style="color: #333333; font-family: inherit;"><span style="white-space: pre-wrap;">The trial will continue until a pre-specified probability of superiority or futility is met, and its success is attributed to collaboration within the medical community.</span></span></p><p style="margin: 0px 0px 1rem; overflow-wrap: break-word;"><span style="color: #333333;"><span style="white-space: pre-wrap;"><a href="https://spiral.co.nz/blog/panoramiccasestudy" target="_blank">Read more about the trial on our blog.</a></span></span></p></div></div><div class="sqs-block image-block sqs-block-image sqs-text-ready" data-block-type="5" id="block-yui_3_17_2_1_1676487639747_9328" style="clear: both; color: #333333; font-size: 16px; height: auto; padding: 17px; position: relative;"><div class="sqs-block-content" id="yui_3_17_2_1_1678665215504_69"><figure class="sqs-block-image-figure image-block-outer-wrapper image-block-v2 design-layout-card combination-animation-site-default individual-animation-site-default individual-text-animation-site-default image-position-left sqs-text-ready animation-loaded" data-scrolled="" data-test="image-block-v2-outer-wrapper" id="yui_3_17_2_1_1678665215504_68" style="display: flex; justify-content: space-between; margin: 0px; position: relative; transform: translateZ(0px);"><div class="intrinsic" id="yui_3_17_2_1_1678665215504_67" style="max-width: initial; position: relative; width: 444.953px;"><div class="image-inset" data-animation-role="image" data-description="" id="yui_3_17_2_1_1678665215504_66" style="min-height: 1px; position: relative;"><div class="sqs-image-shape-container-element content-fit" id="yui_3_17_2_1_1678665215504_65" style="overflow: hidden; position: relative;"><br /></div></div></div></figure></div></div></div></div></div></div></div>JessEsshttp://www.blogger.com/profile/01954522457113433993noreply@blogger.com0tag:blogger.com,1999:blog-10743943.post-29278644748952519592022-11-25T12:31:00.000+13:002022-11-25T12:31:13.036+13:00<h2 style="text-align: left;">Meet Anna - Spiral’s new Data Coordinator</h2><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjPbK--_6T6_QbxXo-Jzr6a8VagJUaiiCO-U8LT575MtaK8p9L2Oipv1Vx4XNOEalQDim_df8Omdv4jda3mqaPLWOBeVZt-k6S5n_Kk5uH0zRmHDf7plBlo2QylSlwH2pumd3KR30MNJsmNRU4ZzWtiZ1V0XhFTTU_eu3ExL5K3B39QINkbJQ/s500/anna-spiral.jpeg" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="500" data-original-width="500" height="320" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjPbK--_6T6_QbxXo-Jzr6a8VagJUaiiCO-U8LT575MtaK8p9L2Oipv1Vx4XNOEalQDim_df8Omdv4jda3mqaPLWOBeVZt-k6S5n_Kk5uH0zRmHDf7plBlo2QylSlwH2pumd3KR30MNJsmNRU4ZzWtiZ1V0XhFTTU_eu3ExL5K3B39QINkbJQ/s320/anna-spiral.jpeg" width="320" /></a></div><div class="separator" style="clear: both; text-align: center;"><br /></div><div class="separator" style="clear: both; text-align: center;"><span style="background-color: white; color: #333333; font-family: Poppins; font-size: 16px; white-space: pre-wrap;">We’re thrilled to have Anna on board to continue building upon our world-class product with our renowned friendly kiwi attitude and can-do approach. </span></div><div class="separator" style="clear: both; text-align: center;"><span style="background-color: white; color: #333333; font-family: Poppins; font-size: 16px; white-space: pre-wrap;"><br /></span></div><div class="separator" style="clear: both; text-align: center;"><span style="background-color: white; color: #333333; font-family: Poppins; font-size: 16px; text-align: start; white-space: pre-wrap;">This newly created position includes</span><strong style="background-color: white; color: #333333; font-family: Poppins; font-size: 16px; overflow-wrap: break-word; text-align: start; white-space: pre-wrap;"> a lot </strong><span style="background-color: white; color: #333333; font-family: Poppins; font-size: 16px; text-align: start; white-space: pre-wrap;">of project testing and data wrangling <a href="https://spiral.co.nz/blog/meetanna" target="_blank">Read more about Anna on our blog</a> »</span></div><br /><p><br /></p>Audreyhttp://www.blogger.com/profile/10419461620219923125noreply@blogger.com0tag:blogger.com,1999:blog-10743943.post-69346844685543072752022-07-13T08:27:00.001+12:002022-07-13T08:27:14.746+12:00Case Study—TAME Study with Dr Glenn Eastwood.<div class="sqs-block html-block sqs-block-html" data-block-type="2" id="block-069a6de89106360bad75" style="background-color: white; clear: none; color: #333333; font-family: Poppins; font-size: 16px; height: auto; padding: 0px 17px 17px; position: relative;"><div class="sqs-block-content" style="outline: none;"><h4 style="color: #0092a8; font-size: calc(0.6vw + 1rem); font-weight: 300; line-height: calc(1.372); margin: 0px 0px 2rem; overflow-wrap: break-word; white-space: pre-wrap;"><strong style="overflow-wrap: break-word;">Global coverage. One platform of choice. </strong></h4><h4 style="color: #0092a8; font-size: calc(0.6vw + 1rem); font-weight: 300; letter-spacing: 0em; line-height: calc(1.372); margin: 0px 0px 2rem; overflow-wrap: break-word; white-space: pre-wrap;"><p class="" style="color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word;"><strong style="overflow-wrap: break-word;">Spiral came on board as the software partner of choice for the TAME trial over five years ago. </strong></p><p class="" style="color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word;">Since then, we've supported the team to take their multicentre randomised control trial to 63 sites in 17 countries. We speak with <a href="https://www.linkedin.com/in/glenn-eastwood-43715666/" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;">Dr Glenn Eastwood</a>, TAME Chief Principal Investigator, about the study and how Spiral has enabled them to produce a database they can be confident in. Alongside TAME, Dr Eastwood is a Senior Research Fellow at the <a href="https://www.monash.edu/medicine/sphpm/anzicrc" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;">Australia New Zealand Intensive Care Research Centre</a> within Monash University.</p><p class="" style="color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word;">The <a href="https://spiral.co.nz/tame-studyplan" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;">TAME trial</a> study compares the targeting of normal arterial carbon dioxide levels to slightly higher than normal carbon dioxide levels for 24 hours in patients admitted to the ICU following cardiac arrest in the community. The research seeks to discover if leveraging off the neuroprotective anti-inflammatory and increasing blood flow effects of having slightly higher carbon dioxide levels in the blood improves the neurological outcome of patients who survive to six months. </p><p class="" style="color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word;"><strong style="color: #0092a8; font-size: calc(0.6vw + 1rem); overflow-wrap: break-word;">Design thinking that embeds multiple comparative data.</strong></p></h4><h4 style="color: #0092a8; font-size: calc(0.6vw + 1rem); font-weight: 300; letter-spacing: 0em; line-height: calc(1.372); margin: 0px 0px 2rem; overflow-wrap: break-word; white-space: pre-wrap;"><p class="" style="color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word;">Spiral's software has allowed him to have confidence in the quality of the wealth of information collected in the TAME trial, as the layout and structure of the software makes it so user-friendly. </p><p class="" style="color: #333333; font-size: 16px; margin: 1rem 0px 1rem 40px; overflow-wrap: break-word;"><em style="overflow-wrap: break-word;">"As a Research Manager and Coordinator at Austin Hospital, I had been a user of the Spiral data management system for previous trials and felt supported by their team. I was impressed with its user-friendliness and good layout, so when it came time for me to choose a trial platform for TAME to run on, I immediately put forward Spiral. I was confident they could expand into other countries with us."</em></p><p class="" style="color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word;"><span style="letter-spacing: 0em;">This study was also unique because it was a harmonised trial embedded in a two by two factorial design. Under serendipitous timing, the </span><a href="https://spiral.co.nz/ttm2-studyplan" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; letter-spacing: 0em; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;">TTM2 trials</a><span style="letter-spacing: 0em;"> were looking for funding simultaneously as us but were looking at temperature management for patients after cardiac arrest. By embedding one trial database and one case report form, the Spiral platform allows sites to do one or both trials, allowing both trials better access and site leverage. </span></p><p class="" style="color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word;">The final participants were recruited in September 2021, and their 6-month follow-ups with trial participants were completed in February, aligned with their initial projections of completion all those years ago. </p><p class="" style="color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word;">Whilst the pandemic could have been a spanner in the works, as different countries came on board at various stages, certain sites could enrol patients when others were not, and vice versa. Now, the team are focused on getting all their data into <a href="https://spiral.co.nz/our-platform" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;">Spinnaker</a>, and we eagerly await the study's findings, which are expected to be released later this year. </p><p class="" style="color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word;">Ensuring that each of the 65 sites taking part in the trial had a good user experience was essential to this study. Dr Eastwood acknowledges this is one of Spiral's greatest strengths, with the software applying common sense with logical and chronological tabs and inputs. </p><p class="" style="color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word;">He also notes that the design's attention to detail provided exceptional ease of use, as he could source the correct information quickly and accurately. </p><div class="sqs-block html-block sqs-block-html" data-block-type="2" id="block-yui_3_17_2_1_1654099888745_7989" style="-webkit-text-stroke-width: 0px; background-color: white; clear: none; color: #333333; font-family: Poppins; font-size: 16px; font-style: normal; font-variant-caps: normal; font-variant-ligatures: normal; font-weight: 300; height: auto; letter-spacing: normal; orphans: 2; padding: 17px; position: relative; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><div class="sqs-block-content" style="outline: none;"><p class="" style="margin: 1rem 0px 1rem 40px; overflow-wrap: break-word; white-space: pre-wrap;"><em style="overflow-wrap: break-word;">"The database field has a prefix that corresponds with the case report form, and that abbreviation is so important for investigators because I want easy access to that variable on that particular row of that table in a paper. Details like that were a blessing."</em></p><p class="" style="margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;">This attention to detail extends further, allowing for the use of different units of measurement. Some sites this trial was running at used millimetres of mercury as a unit of measure, and others used kilopascals. Ensuring that clinicians were able to input their data in a way that made sense to them meant that the users didn't have to do more calculations than necessary, and the database took care of the rest. <br style="overflow-wrap: break-word;" /></p><p class="" style="margin: 1rem 0px 1rem 40px; overflow-wrap: break-word; white-space: pre-wrap;"><em style="overflow-wrap: break-word;">"No matter where you were, you're able to tailor the data coming into the database to suit the site."</em><br style="overflow-wrap: break-word;" /></p><p class="" style="margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;">Dr Eastwood acknowledges the ease of working with the Spiral team, which allows him to focus on his area of expertise. Not only has he found the software reliable and built for purpose, but the simple contract for build and clear monthly maintenance fee have been helpful and reassuring when budgeting research funding. </p></div></div></h4><h4 style="color: #0092a8; font-family: Poppins; font-size: calc(0.6vw + 1rem); font-style: normal; font-weight: 300; letter-spacing: 0em; line-height: calc(1.372); margin: 2rem 0px 0px; overflow-wrap: break-word; text-transform: none; white-space: pre-wrap;"><strong style="font-weight: bold; overflow-wrap: break-word;">Motivated by human compassion.</strong></h4><h4 style="color: #0092a8; font-size: calc(0.6vw + 1rem); font-weight: 300; letter-spacing: 0em; line-height: calc(1.372); margin: 0px 0px 2rem; overflow-wrap: break-word; white-space: pre-wrap;"><div class="sqs-block html-block sqs-block-html" data-block-type="2" style="clear: none; color: #333333; font-size: 16px; height: auto; padding: 17px; position: relative; white-space: normal;"><div class="sqs-block-content" style="outline: none;"></div></div><div class="sqs-block image-block sqs-block-image sqs-col-6 span-6 float float-right sqs-text-ready" data-aspect-ratio="107.6470588235294" data-block-type="5" id="block-yui_3_17_2_1_1654098433374_22231" style="box-sizing: border-box; clear: both; color: #333333; float: right; font-size: 16px; height: auto; margin-left: 17px; padding: 17px; position: relative; white-space: normal; width: 449px; z-index: 10 !important;"><div class="sqs-block-content" id="yui_3_17_2_1_1657657084330_99"><div class="image-block-outer-wrapper layout-caption-overlay-hover design-layout-inline combination-animation-site-default individual-animation-site-default individual-text-animation-site-default animation-loaded" data-test="image-block-inline-outer-wrapper" id="yui_3_17_2_1_1657657084330_98" style="transform: translateZ(0px);"><figure class="
sqs-block-image-figure
intrinsic
" id="yui_3_17_2_1_1657657084330_97" style="margin: 0px auto; max-width: 400px; position: relative;"><div class="image-block-wrapper" data-animation-role="image" id="yui_3_17_2_1_1657657084330_96" style="min-height: 1px; overflow: hidden; position: relative;"><div class="sqs-image-shape-container-element
has-aspect-ratio
" id="yui_3_17_2_1_1657657084330_95" style="overflow: hidden; padding-bottom: 430.586px; position: relative;"><img alt="Dr Glenn Eastwood" class="thumb-image loaded" data-image-dimensions="400x400" data-image-focal-point="0.5,0.5" data-image-id="62978c980811de201b7fb229" data-image-resolution="1000w" data-image="https://images.squarespace-cdn.com/content/v1/602ecffe0a12a5174d2ba1eb/6b22008c-9a79-4f6a-bde6-625b3be730ee/Glenn+Eastwood.jpeg" data-load="false" data-src="https://images.squarespace-cdn.com/content/v1/602ecffe0a12a5174d2ba1eb/6b22008c-9a79-4f6a-bde6-625b3be730ee/Glenn+Eastwood.jpeg" data-type="image" src="https://images.squarespace-cdn.com/content/v1/602ecffe0a12a5174d2ba1eb/6b22008c-9a79-4f6a-bde6-625b3be730ee/Glenn+Eastwood.jpeg?format=1000w" style="border: 0px; height: 430.586px; left: -15.5px; position: absolute; top: 0px; width: 431px;" /></div></div><figcaption class="image-caption-wrapper" style="background: rgba(0, 0, 0, 0.7); box-sizing: border-box; inset: auto 0px 0px; max-height: 100%; opacity: 0; overflow-y: auto; padding: 17px; position: absolute; transition: opacity 0.1s ease-out 0s; visibility: hidden;"><div class="image-caption" style="margin-bottom: -5px; transition: margin-bottom 0.1s ease-out 0s;"><p class="" style="color: #bbbbbb; line-height: 1.68em; margin: 1rem 0px; white-space: pre-wrap;"></p></div></figcaption></figure></div></div></div><div class="sqs-block html-block sqs-block-html" data-block-type="2" id="block-yui_3_17_2_1_1654098433374_28940" style="clear: none; color: #333333; font-size: 16px; height: auto; padding: 17px; position: relative; white-space: normal;"><div class="sqs-block-content" style="outline: none;"><p class="" style="margin: 0px 0px 1rem; overflow-wrap: break-word; white-space: pre-wrap;">This research has been ten years in the making, and it's easy to see that Dr Eastwood's motivation is human compassion. He sees his role as nudging care, little by little, to make improvements in patient outcomes and wants people to be able to hug their kids and enjoy a new part of their life that they might not get otherwise. </p><p class="" style="margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;">He acknowledges that the Spinnaker database allows them to record information to make it easy to turn it into clinical language for their clinicians. This is one of the ways that this study has had participation across so many sites with ease. </p><p class="" data-rte-preserve-empty="true" style="margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"></p><p class="" style="margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;">Moving into the future, data security and data protection are amongst the top priorities of policymakers, particularly in the countries where TAME has operated. Dr Eastwood is grateful for Audrey and the Spiral team's assistance in answering the questions about the Spiral software, with a clear understanding of the ins and outs of their data processes and policy adherence. He acknowledges that systems like Spiral's that are clear on these requirements will become more important as the research community continues to evolve in a connected world. </p><p class="" data-rte-preserve-empty="true" style="margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"></p><p class="" style="margin: 1rem 0px 1rem 40px; overflow-wrap: break-word; white-space: pre-wrap;"><em style="overflow-wrap: break-word;">"Spiral provides a monthly update about the security, the firewall and the system had rarely had any downtime which was reassuring as the trial all around the world and the clinicians taking part needed access around the clock."</em> </p><p class="" style="margin: 1rem 0px 0px 40px; overflow-wrap: break-word; white-space: pre-wrap;"><em style="overflow-wrap: break-word;">"Products that help facilitate clinical research, like Spinnaker, are just going to get more and more important because there's so much data out there and so much opportunity to bring this data together to help create better patient outcomes. I've seen Spiral's flexibility and adaptability and am excited to see how they evolve."</em></p></div></div></h4></div></div>JessEsshttp://www.blogger.com/profile/01954522457113433993noreply@blogger.com0tag:blogger.com,1999:blog-10743943.post-89038751120807271022022-04-15T12:29:00.000+12:002022-04-15T12:29:07.197+12:00Thousands more patients gain access to second ground-breaking antiviral via Panoramic<p> </p><span id="docs-internal-guid-a7578737-7fff-e68b-c32e-2f1b0726066e"><h1 dir="ltr" style="background-color: white; line-height: 1.333332; margin-bottom: 0pt; margin-top: 0pt;"><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi9kes5IigUEKWsMACt2PT83MdAmrgy261TkXEnIBW9AnHC6_uLq3CrkJkqQ5e3rrE2nQel0mbB7qFUFi89kqdzJNB4yQysQHTAGz-M39eVhFr6pUp-Ht7Fhl5SixDUjSvrEcaTjeLGhhndcfRvz65Q3uhUjqYbRBNUiuWl-Bk1Hks7CLmrCg/s2028/Screen%20Shot%202022-04-13%20at%2010.47.17%20AM.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="1358" data-original-width="2028" height="214" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi9kes5IigUEKWsMACt2PT83MdAmrgy261TkXEnIBW9AnHC6_uLq3CrkJkqQ5e3rrE2nQel0mbB7qFUFi89kqdzJNB4yQysQHTAGz-M39eVhFr6pUp-Ht7Fhl5SixDUjSvrEcaTjeLGhhndcfRvz65Q3uhUjqYbRBNUiuWl-Bk1Hks7CLmrCg/s320/Screen%20Shot%202022-04-13%20at%2010.47.17%20AM.png" width="320" /></a></div><br /><span style="background-color: transparent; color: #34318a; font-family: "Open Sans", sans-serif; font-size: 12pt; white-space: pre-wrap;"><br /></span></h1><div><span style="background-color: transparent; color: #34318a; font-family: "Open Sans", sans-serif; font-size: 12pt; white-space: pre-wrap;"><br /></span></div><h1 dir="ltr" style="background-color: white; line-height: 1.333332; margin-bottom: 0pt; margin-top: 0pt;"><span style="background-color: transparent; color: #34318a; font-family: "Open Sans", sans-serif; font-size: 12pt; white-space: pre-wrap;">A new anti-viral, Paxlovid, has recently been added to the PANORAMIC national study in the UK. </span></h1><p dir="ltr" style="background-color: white; line-height: 1.2; margin-bottom: 0pt; margin-top: 0pt; padding: 15pt 0pt 15pt 0pt;"><span style="background-color: transparent; color: #34318a; font-family: "Open Sans", sans-serif; font-size: 12pt; font-variant-east-asian: normal; font-variant-numeric: normal; vertical-align: baseline; white-space: pre-wrap;">Thousands more vulnerable people in England are now eligible to receive the UK’s second oral antiviral treatment for COVID-19. Paxlovid reduced the risk of hospitalisation or death by 88% in clinical trials and is already available directly through the NHS to highest-risk patients. The UK has procured more antivirals per head than any other country in Europe with over 4.98 million courses ordered so far.</span></p><p dir="ltr" style="background-color: white; line-height: 1.2; margin-bottom: 0pt; margin-top: 0pt; padding: 0pt 0pt 15pt 0pt;"><span style="background-color: transparent; color: #34318a; font-family: "Open Sans", sans-serif; font-size: 12pt; font-variant-east-asian: normal; font-variant-numeric: normal; vertical-align: baseline; white-space: pre-wrap;">The PANORAMIC national study is the UK’s fastest-ever recruiting clinical trial of its kind, run by the University of Oxford in close collaboration with GP hubs. It is already available directly through the NHS to those whose immune systems mean they are at higher risk of serious illness who test positive for the virus – including those who are immunocompromised, cancer patients or those with Down’s syndrome.</span></p><p dir="ltr" style="background-color: white; line-height: 1.2; margin-bottom: 0pt; margin-top: 0pt; padding: 0pt 0pt 15pt 0pt;"><span style="background-color: transparent; color: #34318a; font-family: "Open Sans", sans-serif; font-size: 12pt; font-variant-east-asian: normal; font-variant-numeric: normal; vertical-align: baseline; white-space: pre-wrap;">The PANORAMIC study makes antivirals available to a large number of patients while collecting further data on how the antivirals work where the majority of the adult population is vaccinated. It ensures antivirals are being used in the most effective way and is crucial in ensuring clinicians have the full information to prescribe antiviral treatments to patients in future</span></p><p dir="ltr" style="background-color: white; line-height: 1.2; margin-bottom: 0pt; margin-top: 0pt; padding: 0pt 0pt 15pt 0pt;"><span style="background-color: transparent; color: #34318a; font-family: "Open Sans", sans-serif; font-size: 12pt; font-style: italic; font-variant-east-asian: normal; font-variant-numeric: normal; font-weight: 700; vertical-align: baseline; white-space: pre-wrap;">‘The addition of Paxlovid to the ground-breaking PANORAMIC study is an important milestone and will help us understand who benefits most from these treatments.’</span><span style="background-color: transparent; color: #34318a; font-family: "Open Sans", sans-serif; font-size: 12pt; font-variant-east-asian: normal; font-variant-numeric: normal; vertical-align: baseline; white-space: pre-wrap;"> - UK Health and Social Care Secretary Sajid Javid</span><span style="color: #0b0c0c; font-family: Arial; font-size: 14.5pt; font-variant-east-asian: normal; font-variant-numeric: normal; vertical-align: baseline; white-space: pre-wrap;"> </span></p><p dir="ltr" style="line-height: 1.2; margin-bottom: 0pt; margin-top: 0pt;"><span style="color: #34318a; font-family: "Open Sans", sans-serif; font-size: 12pt; font-variant-east-asian: normal; font-variant-numeric: normal; vertical-align: baseline; white-space: pre-wrap;">While vaccines remain the most important first line of defence, antivirals target the virus at an early stage, preventing progression to more severe, or even critical, symptoms.</span></p><br /><p dir="ltr" style="line-height: 1.2; margin-bottom: 0pt; margin-top: 0pt;"><span style="color: #34318a; font-family: "Open Sans", sans-serif; font-size: 12pt; font-variant-east-asian: normal; font-variant-numeric: normal; vertical-align: baseline; white-space: pre-wrap;">The UK government has secured 2.75 million courses of Paxlovid (PF-07321332 and ritonavir), made by Pfizer. Those who enrol in the PANORAMIC study will be randomly allocated to receive either an antiviral treatment in addition to standard NHS care, or standard NHS care only.</span></p><br /><p dir="ltr" style="line-height: 1.2; margin-bottom: 0pt; margin-top: 0pt;"><span style="color: #34318a; font-family: "Open Sans", sans-serif; font-size: 12pt; font-variant-east-asian: normal; font-variant-numeric: normal; vertical-align: baseline; white-space: pre-wrap;">As a study in our manifest, Spiral has now added Paxlovid to the</span><a href="https://twitter.com/PANORAMICTrial" style="text-decoration-line: none;"><span style="color: #34318a; font-family: "Open Sans", sans-serif; font-size: 12pt; font-variant-east-asian: normal; font-variant-numeric: normal; vertical-align: baseline; white-space: pre-wrap;"> PANORAMIC Trial</span></a><span style="color: #34318a; font-family: "Open Sans", sans-serif; font-size: 12pt; font-variant-east-asian: normal; font-variant-numeric: normal; vertical-align: baseline; white-space: pre-wrap;"> platform. For Spiral and the team, this means lots of coding and extensions to the database to get everything ready for randomising. We’re so excited to see the growth in this study! Watch this space as we bring you more news on this aspect of the trial as it develops!</span></p><br /><p dir="ltr" style="line-height: 1.2; margin-bottom: 0pt; margin-top: 0pt;"><span style="color: #34318a; font-family: "Open Sans", sans-serif; font-size: 12pt; font-variant-east-asian: normal; font-variant-numeric: normal; vertical-align: baseline; white-space: pre-wrap;">Sources:</span></p><br /><p dir="ltr" style="line-height: 1.2; margin-bottom: 0pt; margin-top: 0pt;"><a href="https://www.gov.uk/government/news/thousands-more-patients-to-access-second-ground-breaking-antiviral" style="text-decoration-line: none;"><span style="color: #1155cc; font-family: "Open Sans", sans-serif; font-size: 12pt; font-variant-east-asian: normal; font-variant-numeric: normal; text-decoration-line: underline; text-decoration-skip-ink: none; vertical-align: baseline; white-space: pre-wrap;">UK Government</span></a></p><p dir="ltr" style="line-height: 1.2; margin-bottom: 0pt; margin-top: 0pt;"><a href="https://www.panoramictrial.org/" style="text-decoration-line: none;"><span style="color: #1155cc; font-family: "Open Sans", sans-serif; font-size: 12pt; font-variant-east-asian: normal; font-variant-numeric: normal; text-decoration-line: underline; text-decoration-skip-ink: none; vertical-align: baseline; white-space: pre-wrap;">Panoramic Trial</span></a></p><div><br /></div></span>JessEsshttp://www.blogger.com/profile/01954522457113433993noreply@blogger.com0tag:blogger.com,1999:blog-10743943.post-82376022608277098812022-03-14T14:45:00.001+13:002022-03-14T14:47:03.633+13:00REMAP-CAP reaches new milestone!<p><a href="https://spiral.co.nz/remapcap-studyplan" style="background-attachment: initial; background-clip: initial; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; font-family: Poppins; font-size: 16px; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;" target="_blank"></a></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/a/AVvXsEgXqsLCmYfvmjnAe1BdaX3XRY4u_k7fH_KtZH8N9aNbsCDdI6M9ipM_VA0RD4rdI3o7hSYOh8md-ZDPVjKGu1AQO5BFCgvHuk-bPEUqX2fnv_EDWcMk8-M48o6dt8vXUbwYwwaYagTlJZk13lrTbhpGEb__RTN3qtz3Tz6aNagbpTD9I-bxPg=s4300" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="2867" data-original-width="4300" height="213" src="https://blogger.googleusercontent.com/img/a/AVvXsEgXqsLCmYfvmjnAe1BdaX3XRY4u_k7fH_KtZH8N9aNbsCDdI6M9ipM_VA0RD4rdI3o7hSYOh8md-ZDPVjKGu1AQO5BFCgvHuk-bPEUqX2fnv_EDWcMk8-M48o6dt8vXUbwYwwaYagTlJZk13lrTbhpGEb__RTN3qtz3Tz6aNagbpTD9I-bxPg=s320" width="320" /></a></div><br />REMAP-CAP<span style="background-color: white; color: #333333; font-family: Poppins; font-size: 16px; white-space: pre-wrap;">, the Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia, has recently hit a significant date in its trial history, celebrating two years since the first Covid-19 ICU patient was randomised into the trial.</span><p></p><p><span style="background-color: white; color: #333333; font-family: Poppins; font-size: 16px; white-space: pre-wrap;">Looking back on the trial and the COVID-19 climate which we still find ourselves in, it’s incredible to see how quickly things happened. On the 10th of March 2020, the first patient was enrolled at </span><a href="https://mail.google.com/mail/u/2/#inbox" style="background-attachment: initial; background-clip: initial; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; font-family: Poppins; font-size: 16px; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;" target="_blank">Royal Melbourne Hospital</a><span style="background-color: white; color: #333333; font-family: Poppins; font-size: 16px; white-space: pre-wrap;">, with the second following on the 13th of March. On the 17th we saw another 4 patients enrol before the floodgates opened. </span></p><p><span style="background-color: white; color: #333333; font-family: Poppins; font-size: 16px; white-space: pre-wrap;">Now two years on since the first enrolment, we have watched as the total number of patients has climbed to an astounding 11,032 with almost 20,000 randomisations. 17,581 of these were with suspected or proven Covid-19. There are now 357 active sites across the globe working within this trial and 55 current or completed interventions in 16 domains. </span></p><p><a class="image-slide-anchor content-fill" role="presentation" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-bottom: none; color: inherit; cursor: default; display: inline; font-family: Poppins; font-size: 16px; height: 0px; overflow: hidden; padding-bottom: 210.992px; width: 281.328px;"></a><a class="image-slide-anchor content-fill" role="presentation" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; border-bottom: none; color: inherit; cursor: default; display: inline; height: 0px; overflow: hidden; padding-bottom: 210.992px; width: 281.328px;"><span style="white-space: pre-wrap;">We’ve seen some remarkable and promising results gained from these domains during these two years. </span></a><a href="https://spiral.co.nz/blog/therapeutic-anticoagulation-in-non-critically-ill-patients-with-covid-19" style="background-attachment: initial; background-clip: initial; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;" target="_blank">Therapeutic-dose anticoagulation with heparin</a><span style="white-space: pre-wrap;"> has shown to increase the probability of survival for those hospitalised as non-critically ill patients with Covid-19. We’ve also learnt how </span><a href="https://spiral.co.nz/blog/full-dose-blood-thinners-bebefit-moderately-ill-covid-19-patients" style="background-attachment: initial; background-clip: initial; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;" target="_blank">full-dose blood thinners benefit moderately ill COVID-19 patients</a><span style="white-space: pre-wrap;"> and have seen how </span><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2100433" style="background-attachment: initial; background-clip: initial; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;">tocilizumab and sarilumab are equally effective for the treatment of patients with severe COVID-19</a><span style="white-space: pre-wrap;"> - the most effective interventions included in this particular domain.</span></p><p><span style="background-color: white; color: #333333; font-family: Poppins; font-size: 16px; white-space: pre-wrap;">Before Covid-19 first made itself known, the world of clinical trials was at a remarkably different place. The challenges that existed then are still present now, but the global pandemic has highlighted just how easily health risks can cross borders. We’ve also witnessed the speed at which things can change, demonstrating a need for global cooperation and unity within the medical community. This pandemic has mobilised researchers worldwide on a scale and timeframe that has never before been witnessed for one disease. </span></p><p><span style="background-color: white; color: #333333; font-family: Poppins; font-size: 16px; white-space: pre-wrap;">The immense pressure that has been placed upon researchers, regulators, trial technicians, doctors and nurses (the list goes on) has been undeniable. We’ve seen how important well-designed randomised clinical trials are for both patients and medical staff as well as a need to move quickly in a time of incredible uncertainty.</span></p><p><span style="background-color: white; color: #333333; font-family: Poppins; font-size: 16px; white-space: pre-wrap;">Spiral has been involved in the REMAP-CAP clinical trial for the past two years. We have dedicated several members of staff to developing and delivering the software needed to perform this study within our Spinnaker platform. Being highly adaptable and flexible in this current global environment has been a crucial aspect for our team, ensuring that we deliver exactly what is needed to those working on the frontline, making trials like </span><a href="https://www.remapcap.org/" style="background-attachment: initial; background-clip: initial; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; font-family: Poppins; font-size: 16px; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;" target="_blank">REMAP-CAP</a><span style="background-color: white; color: #333333; font-family: Poppins; font-size: 16px; white-space: pre-wrap;"> faster, easier and smarter.</span></p><p><span style="background-color: white; color: #333333; font-family: Poppins; font-size: 16px; white-space: pre-wrap;">To put it simply, worldwide, REMAP-CAP has been one of the most important critical care trials of the pandemic, one that Spiral continues to be proud to be a part of. </span></p><p><strong style="background-color: white; color: #333333; font-family: Poppins; font-size: 16px; overflow-wrap: break-word; white-space: pre-wrap;"><em style="overflow-wrap: break-word;">‘It’s an absolute privilege to be working on this project with the global REMAP-CAP family. The past two years have been crazy - although we were preparing the platform for a pandemic nothing prepared us for the global nature of this pandemic, the speed of its spread or how often the disease adapted. The dedication of the team at Spiral to meet these challenges has been astounding’ - </em></strong><a href="https://spiral.co.nz/audrey" style="background-attachment: initial; background-clip: initial; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; font-family: Poppins; font-size: 16px; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;" target="_blank"><strong style="overflow-wrap: break-word;"><em style="overflow-wrap: break-word;">Audrey Shearer</em></strong></a><strong style="background-color: white; color: #333333; font-family: Poppins; font-size: 16px; overflow-wrap: break-word; white-space: pre-wrap;"><em style="overflow-wrap: break-word;">, Spiral Founder and CEO</em></strong></p>JessEsshttp://www.blogger.com/profile/01954522457113433993noreply@blogger.com0tag:blogger.com,1999:blog-10743943.post-87965800416559110192022-03-01T12:56:00.001+13:002022-03-24T12:58:22.956+13:00The Panoramic Trial Reaches 10,000 Enrolments!<p></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgq5z6zYxBgleSlkEPinktd1GJ1cI3eUBCOGwGgKUVWgEEDaL2OaCYUOiFG8qwgDTH8BX-FR8mss9Ay5j8U7q8cIXgnoN4phQ_-Vrc92UEk1ah5uLwN4MO2YqZ3fEUzSgVu6ekI7ZGZUKS5c5Yw_giYQ4WC0JNOMz9LMEvqf748rXm79THxSg/s1200/Panoramic%20trial.jpeg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="375" data-original-width="1200" height="100" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgq5z6zYxBgleSlkEPinktd1GJ1cI3eUBCOGwGgKUVWgEEDaL2OaCYUOiFG8qwgDTH8BX-FR8mss9Ay5j8U7q8cIXgnoN4phQ_-Vrc92UEk1ah5uLwN4MO2YqZ3fEUzSgVu6ekI7ZGZUKS5c5Yw_giYQ4WC0JNOMz9LMEvqf748rXm79THxSg/s320/Panoramic%20trial.jpeg" width="320" /></a></div><br /> <p></p><div class="sqs-block quote-block sqs-block-quote null" data-block-type="31" id="block-yui_3_17_2_1_1648078717990_2020" style="background-color: white; clear: both; color: #333333; font-family: Poppins; height: auto; padding: 0px 17px 17px; position: relative; text-align: left;"><div class="sqs-block-content"><figure class="block-animation-none" style="margin: 1em 0px;"><p style="letter-spacing: 0em; line-height: 1.8em; margin: 0px;">“We want to thank every single one of the 10,000 people who have taken part in the PANORAMIC trial to date. Your vital contribution to this remarkable study will provide key evidence in record time for a potentially game-changing class of new COVID-19 treatments.”</p><figure class="block-animation-none" style="margin: 1em 0px;"><figcaption class="source" style="letter-spacing: 0em; line-height: 1.2em; text-align: left;">— Dr William van't Hoff, NIHR</figcaption></figure><p></p></figure></div></div><div class="sqs-block html-block sqs-block-html" data-block-type="2" id="block-b31ebc3941a5678b787e" style="background-color: white; clear: none; color: #333333; font-family: Poppins; height: auto; padding: 17px; position: relative; text-align: left;"><div class="sqs-block-content" style="outline: none;"><p class="" style="margin: 0px 0px 1rem; overflow-wrap: break-word; white-space: pre-wrap;">Over ten thousand participants from right across the UK have now taken part in the <a href="https://www.nihr.ac.uk/" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;" target="_blank">NIHR</a>-funded and supported <a href="https://www.panoramictrial.org/" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;" target="_blank">PANORAMIC</a> trial - the world’s largest study into new antiviral treatments against COVID-19 in community, ambulatory care.</p><p class="" style="margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;">This trial was recently launched in December last year but only took a few months to reach this milestone. It is also believed to be the world’s largest study of community-based treatments for acute COVID-19, in addition to the UK’s fastest ever recruiting interventional trial delivered through primary care.</p><p class="" style="margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;">Our <a href="https://spiral.co.nz/home" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;" target="_blank">Spiral</a> software is helping the trial to rapidly generate evidence on which of the people suffering with COVID-19 at home and in the community are helped the most by the new antiviral treatments. All without needing to be treated in hospital.</p><p class="" style="margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;">More in depth information on the Panoramic trial and its progress can be found <a href="https://www.nihr.ac.uk/news/over-ten-thousand-participants-enrol-in-worlds-largest-covid-19-antiviral-study/29951" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;">here</a> via NIHR.</p></div></div>JessEsshttp://www.blogger.com/profile/01954522457113433993noreply@blogger.com0tag:blogger.com,1999:blog-10743943.post-89307142966673402902022-01-27T10:44:00.002+13:002022-01-27T10:44:58.698+13:00Saline just as effective as more expensive ‘balanced’ solutions - PLUS Study finds<p style="text-align: left;"></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/a/AVvXsEgyXy5QreJq5AO_1TtSUPNf1lEmWUTCzITxZJJQlQ8fVHWBvMlZGzvqvALKsCRC1saD2Y9IeGhFSnj3I3ap_gJOEVBEHeHRFnmL3WXUZsDwGvUps5zykvhqKn8OMX6qZf77c4f7PETL2ma5BzKxMse50OG_ZXTjr95uuVIsKfLIH6VvxgZj3A=s5955" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="3970" data-original-width="5955" height="213" src="https://blogger.googleusercontent.com/img/a/AVvXsEgyXy5QreJq5AO_1TtSUPNf1lEmWUTCzITxZJJQlQ8fVHWBvMlZGzvqvALKsCRC1saD2Y9IeGhFSnj3I3ap_gJOEVBEHeHRFnmL3WXUZsDwGvUps5zykvhqKn8OMX6qZf77c4f7PETL2ma5BzKxMse50OG_ZXTjr95uuVIsKfLIH6VvxgZj3A=s320" width="320" /></a></div><span style="font-family: arial;"><span style="background-color: white; color: #333333; font-size: 16px; white-space: pre-wrap;"><p style="text-align: left;"><span style="font-family: arial;"><span style="background-color: white; color: #333333; font-size: 16px; white-space: pre-wrap;"><br /></span></span></p>The long-awaited results are finally here for the PLUS trial, an application in Spiral’s study manifest. </span></span><p></p><p style="text-align: left;"><span style="font-family: arial;"><span style="background-color: white; color: #333333; font-size: 16px; white-space: pre-wrap;">The aim of <a href="https://spiral.co.nz/plus-studyplan">PLUS</a> was to conduct a multi-centre, blinded, randomised, controlled trial (RCT) to determine whether fluid resuscitation and therapy with a "balanced" crystalloid solution (Plasma-Lyte 148®) decreases 90-day mortality in critically ill patients requiring fluid resuscitation when compared with the same treatment using 0.9% sodium chloride (saline). </span></span></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; text-align: left; white-space: pre-wrap;"><span style="font-family: arial;">The newly published results have determined that intravenous fluids used in intensive care such as the commonly used saline is as effective at keeping people alive and their organs functioning as more expensive ‘balanced’ solutions.</span></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; text-align: left; white-space: pre-wrap;"><span style="font-family: arial;">The results not only provide doctors with greater certainty about the safety and benefits of saline solution but also have broader implications for treatment availability and costs around the world.</span></p><blockquote style="background-color: white; color: #333333; font-size: 16px; overflow-wrap: break-word; text-align: left;"><p class="" style="margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;"><em style="overflow-wrap: break-word;">“Just about every patient admitted to the Intensive Care Unit (ICU) will receive intravenous fluids for resuscitation or as part of standard treatment,” </em>said Professor Simon Finfer AO, an ICU physician and senior researcher at The George Institute.</span></p><p class="" style="margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><em style="overflow-wrap: break-word;"><span style="font-family: arial;">“However, the best choice of fluid has been a longstanding issue of debate as some fluids were approved and licensed for use based on trials in small numbers of patients looking only at short term outcomes.”</span></em></p></blockquote><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; text-align: left; white-space: pre-wrap;"><span style="font-family: arial;">Reports of intravenous solutions being used to treat critically ill patients date back almost 200 years ago. However, due to a lack of robust data, controversy over the choice of intravenous fluids has continued in the medical industry. The question has remained: In critically ill adults, does the use of balanced crystalloid solutions compared with saline reduce mortality and/or the occurrence of acute kidney injury? </span></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; text-align: left; white-space: pre-wrap;"><span style="font-family: arial;">To determine this, researchers at <a href="https://www.georgeinstitute.org/" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;">The George Institue for Global Health</a> designed a clinical trial with the team at <a href="https://spiral.co.nz/plus-studyplan" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;">Spiral</a> - the Plasma-Lyte 148® versUs Saline (PLUS) study - which involved over 5,000 patients across 53 sites in Australia and New Zealand.</span></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; text-align: left; white-space: pre-wrap;"><span style="font-family: arial;">They recruited adult patients admitted to participating ICUs during the study period who needed intravenous fluid resuscitation for their underlying medical condition. The patients were followed for a period of 90 days after treatment as previous research had shown around one in four would be at risk of dying within this timeframe.</span></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; text-align: left; white-space: pre-wrap;"><span style="font-family: arial;">The research team primarily looked at rates of death in patients who were given the BMES or saline while they were in the ICU. At 90 days after the treatment, the same number of patients in the BMES and saline groups had died.</span></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; text-align: left; white-space: pre-wrap;"><span style="font-family: arial;">The number of days that the patients required mechanical ventilation, kidney dialysis, their survival time in the ICU and in hospital, as well as major measures of healthcare costs were similar between the groups.</span></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; text-align: left; white-space: pre-wrap;"><span style="font-family: arial;"><em style="overflow-wrap: break-word;">“We found no evidence that using a balanced multi-electrolyte solution in the ICU, compared to saline, reduced risk of death or acute kidney injury in critically ill adults,”</em> said Prof Finfer.</span></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; text-align: left; white-space: pre-wrap;"><span style="font-family: arial;">These results have far-reaching implications for the medical industry. Each year in Australia 160,000 people are admitted to ICU. It is one of the most expensive aspects of healthcare with one day in ICU costing a minimum of $4,000. With high demand for ICU beds, resources and expertise, even a small difference in outcomes may result in important clinical and economic effects at the population level. </span></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; text-align: left; white-space: pre-wrap;"><span style="font-family: arial;">Spiral is proud to be a part of this study, making a tangible contribution to the medical industry, its professionals and patients. </span></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; text-align: left; white-space: pre-wrap;"><span style="font-family: arial;">Dive deeper:</span></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; text-align: left; white-space: pre-wrap;"><a href="https://www.georgeinstitute.org.au/media-releases/australian-study-set-to-guide-the-treatment-of-critically-ill-patients-worldwide" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;"><span style="overflow-wrap: break-word;"><span style="font-family: arial;">The George Institute for Global Health</span></span></a></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; text-align: left; white-space: pre-wrap;"><a href="https://evidence.nejm.org/doi/full/10.1056/EVIDoa2100010" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;"><span style="overflow-wrap: break-word;"><span style="font-family: arial;">The New England Journal of Medicine</span></span></a></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; text-align: left; white-space: pre-wrap;"><a href="https://criticalcarereviews.com/" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;"><span style="overflow-wrap: break-word;"><span style="font-family: arial;">Critical Care Reviews</span></span></a></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; text-align: left; white-space: pre-wrap;"><a href="https://www.aninews.in/news/science/research-to-guide-treatment-of-critically-ill-patients-globally20220119134123/" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;"><span style="overflow-wrap: break-word;"><span style="font-family: arial;">ANI - South Asia’s Leading Multimedia News Agency</span></span></a></p><br /><p style="height: 0px; text-align: left;"><br /></p>JessEsshttp://www.blogger.com/profile/01954522457113433993noreply@blogger.com0Wellington, New Zealand-41.2923814 174.7787463-90 104.4662463 11.414748734460247 -114.90875370000003tag:blogger.com,1999:blog-10743943.post-57716225476029478542021-12-16T11:38:00.001+13:002022-01-19T11:39:53.872+13:00It's official! The Panoramic trial is all go!<p><span style="background-color: white; color: #333333; font-size: 16px; white-space: pre-wrap;"></span></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/a/AVvXsEjS65BDPIUqURLH0lh6OoP9q0tSQkQwMJRnuciT7_S2-D4bZRG8nginhwZoIzDzPA-H6E6PQwYfWjmquzPbttAGVbc0aE791KHt-V41jHZPq2i5_uYTD5bCQ51rQ1bYomVPqeyPyhFqn1GFII9bSyU1DBDyrZl6CLxQ-lgyo7RQwY9oIAIxEA=s1000" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="427" data-original-width="1000" height="137" src="https://blogger.googleusercontent.com/img/a/AVvXsEjS65BDPIUqURLH0lh6OoP9q0tSQkQwMJRnuciT7_S2-D4bZRG8nginhwZoIzDzPA-H6E6PQwYfWjmquzPbttAGVbc0aE791KHt-V41jHZPq2i5_uYTD5bCQ51rQ1bYomVPqeyPyhFqn1GFII9bSyU1DBDyrZl6CLxQ-lgyo7RQwY9oIAIxEA=s320" width="320" /></a></div><br /><span style="font-family: arial;"><br /></span><p></p><p><span style="background-color: white; color: #333333; font-size: 16px; white-space: pre-wrap;"><span style="font-family: arial;">Recently we announced our involvement in another incredibly exciting trial, aimed at finding effective treatments for people in the community which will prevent people from being hospitalised with Covid-19.</span></span></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">This trial was awarded funding through the <a href="https://www.nihr.ac.uk/" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;"><span style="overflow-wrap: break-word;">National Institute for Health Research (NIHR)</span></a> to work with several UK universities and carry out a first-of-its-kind clinical trial, testing novel antiviral COVID-19 treatments for use early on in the illness by people in the community with COVID-19 who are at higher risk of complications.</span></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">Known as PANORAMIC, this trial is led by <a href="https://www.phc.ox.ac.uk/research/institutes-units/phctrials" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;"><span style="overflow-wrap: break-word;">Oxford University’s Primary Care Clinical Trials Unit</span></a>, while the delivery of the trial will be supported by the<a href="https://www.nihr.ac.uk/explore-nihr/support/clinical-research-network.htm" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;"><span style="overflow-wrap: break-word;"> NIHR Clinical Research Network </span></a>and devolved administrations.</span></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">In a new development, we’re thrilled to report that the UK government has announced that thousands of the UK’s most vulnerable people will be among the first in the world to access these life-saving, cutting-edge antiviral and antibody treatments from December.</span></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><strong style="overflow-wrap: break-word;"><span style="font-family: arial;"><em style="overflow-wrap: break-word;">“This opens up a new era for the treatment of COVID-19, one where we can begin to cover every phase of contracting this deadly disease – whether it be before you catch it, just after you catch it, if you develop symptoms or if you require hospital care.” - </em>UK Health and Social Care Secretary Sajid Javid</span></strong></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">The study will be trialling the use of Molnupiravir, an anti-viral drug shown in clinical trials to reduce the risk of hospitalisation or death for at-risk, non-hospitalised adults with mild to moderate COVID-19 by 30%.</span></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">Taking part in the study will require participants to complete a daily diary for 28 days through the <a href="https://www.panoramictrial.org/" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;" target="_blank">PANORAMIC website</a> or receive a phone call from the trial team on days 7, 14 and 28 to speak about their symptoms. The first set of results from the trial is anticipated in early 2022.</span></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">Spiral will be supporting with our savvy software platform and our ability to pivot with change. Unlike others, we can adapt our platform for Novel Trials or studies that use unusual design methodologies. We’re excited to keep you informed about this groundbreaking trial - one that we feel privileged to be a part of.</span></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">Keep up to date with the Panoramic trial via our Trial Hub page <a href="https://spiral.co.nz/panoramic-studyplan" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;" target="_blank">here</a>. We will be refreshing it with new information as and when it is made available.</span></p><h4 style="background-color: white; color: #0092a8; font-size: calc(0.6vw + 1rem); font-weight: 300; line-height: 1.372; margin: 2rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">Dive Deeper:</span></h4><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><a href="https://www.gov.uk/government/news/uks-most-vulnerable-people-to-receive-life-saving-covid-19-treatments-in-the-community" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;" target="_blank"><span style="font-family: arial;">Press Release - UK’S Most Vulnerable People to receive life-saving Covid-19 treatments in the community</span></a></p><div><br /></div>JessEsshttp://www.blogger.com/profile/01954522457113433993noreply@blogger.com0tag:blogger.com,1999:blog-10743943.post-74694840627535693282021-11-15T11:32:00.001+13:002022-01-19T11:34:02.340+13:00Meet Adam - One of our developers here at Spiral<p><span style="background-color: white; color: #333333; font-size: 16px; white-space: pre-wrap;"></span></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/a/AVvXsEjNVwPd5GsGjN9HgYrM2JKn-sxPBsV5P4NZy6hyCwMhhRrmTz8TYnIwUEuTzF3DkY-VjNncI_UKSzh7hgtQ9dYgIdR2JdaK-bAC4x2BVUfn9F_8vKc89RgAj7z_cdQJFjnmdxtXubqEm-Y9lei8k7hqOHmo7_yuKZkZJKTOSzEfigaAMGtYKg=s1708" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="1130" data-original-width="1708" height="212" src="https://blogger.googleusercontent.com/img/a/AVvXsEjNVwPd5GsGjN9HgYrM2JKn-sxPBsV5P4NZy6hyCwMhhRrmTz8TYnIwUEuTzF3DkY-VjNncI_UKSzh7hgtQ9dYgIdR2JdaK-bAC4x2BVUfn9F_8vKc89RgAj7z_cdQJFjnmdxtXubqEm-Y9lei8k7hqOHmo7_yuKZkZJKTOSzEfigaAMGtYKg=s320" width="320" /></a></div><br /><span style="font-family: arial;"><br /></span><p></p><p><span style="background-color: white; color: #333333; font-family: arial; font-size: 16px; white-space: pre-wrap;">Meet Adam. As the newest member to join our Spiral team, Adam has been with us for just over 6 months but has already brought with him a wealth of enthusiasm and keenness to take on a challenge.</span></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">Becoming a developer was not a career Adam had initially planned for. Although he always had an interest in subjects like science and software, Adam fell into hospitality, working as a chef for 10 years as a way to support his studies in mechanical engineering. </span></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">Now based in Wellington, Adam and his partner had been living in Germany for the last three years. However, like many Kiwis abroad, the outbreak of Covid forced them to reconsider their options, resulting in a move home. Realising he was no longer challenged in his current role, the move allowed Adam to reassess where he was in his career and make the decision to start fresh.</span></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">A software development boot camp in Wellington kickstarted his journey on his new career path. Not long after, a job posting for Spiral came through his career advisor. This immediately piqued Adam’s interest and so he contacted <a href="https://spiral.co.nz/audrey" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;" target="_blank">Audrey</a> the same day. A job interview led to an offer and the rest, as they say, is history. </span></p><blockquote style="background-color: white; color: #333333; font-size: 16px; overflow-wrap: break-word;"><p class="" style="margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><strong style="overflow-wrap: break-word;"><em style="overflow-wrap: break-word;"><span style="font-family: arial;">‘I feel lucky that Audrey decided to take a chance on me, considering I was new to the industry and a bit older.’</span></em></strong></p></blockquote><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">Although still relatively new to the role and the industry, Adam loves the challenges that every day brings. He’s the kind of person who loves to push himself and enjoys overcoming obstacles. With software engineering, you don’t necessarily know the answer straight away but it’s your job to go and find the best solution. This is an aspect of the job that Adam particularly enjoys. </span></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">Having been used to working in busy, cramped environments like kitchens, working remotely from home is a new experience for Adam but one that he is acclimatising to well. He enjoys the flexibility it brings and the lack of distractions. Despite having met his team in real life only a handful of times, he already feels like he knows them well thanks to online meetings, Slack and Facetime. </span></p><blockquote style="background-color: white; color: #333333; font-size: 16px; overflow-wrap: break-word;"><p class="" style="margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><strong style="overflow-wrap: break-word;"><em style="overflow-wrap: break-word;"><span style="font-family: arial;">‘All the people I interact with are really smart and on to it, I feel lucky to work alongside them as well as our clients - it’s inspiring.’</span></em></strong></p></blockquote><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">Although happy to leave his hospitality days behind, there are some values that Adam has brought forward into his new role: </span></p><blockquote style="background-color: white; color: #333333; font-size: 16px; overflow-wrap: break-word;"><p class="" style="margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><strong style="overflow-wrap: break-word;"><em style="overflow-wrap: break-word;"><span style="font-family: arial;">‘If you’ve got time for leaning you’ve got time for cleaning’ </span></em></strong></p></blockquote><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">A saying most often heard in the kitchen, Adam likes to apply this to his work at Spiral, knowing that there is always something that he can be putting his best effort into. He’s also the type of person who isn’t happy settling for ‘good enough.’ Adam likes to set high standards for himself and those around him and operates accordingly. </span></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">While cooking is still something he loves to do for friends and family on the weekend, he is much happier solving problems daily in his role at Spiral, knowing that his work is creating a tangible difference in the world. </span></p><blockquote style="background-color: white; color: #333333; font-size: 16px; margin-bottom: 0px; overflow-wrap: break-word;"><p class="" style="margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><strong style="overflow-wrap: break-word;"><em style="overflow-wrap: break-word;"><span style="font-family: arial;">‘My role is busy and challenging and at the same time it’s incredibly rewarding - that’s what I love about it.’</span></em></strong></p></blockquote>JessEsshttp://www.blogger.com/profile/01954522457113433993noreply@blogger.com0tag:blogger.com,1999:blog-10743943.post-60625377260854710612021-11-02T11:28:00.002+13:002022-01-19T11:35:05.082+13:00Spiral joins first-of-its-kind clinical trial - continuing the fight against Covid<p></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/a/AVvXsEhBByk6HCEoz1Jb5sOxrGDnYtjHBLyPjL6ehEyt-i5-STBE18l3UE3U0-Ij912I6Bjqzw2PikGga0APZAnUeQwWY32VURj5hR_j5mlt9dO60imFAOykYr9mPKrLRuqHQUQ9O44EJf9Myswf6x7O4QfDYGu-PjPDzy5BuaB5a_o8qCpm_7x0sg=s1200" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="375" data-original-width="1200" height="100" src="https://blogger.googleusercontent.com/img/a/AVvXsEhBByk6HCEoz1Jb5sOxrGDnYtjHBLyPjL6ehEyt-i5-STBE18l3UE3U0-Ij912I6Bjqzw2PikGga0APZAnUeQwWY32VURj5hR_j5mlt9dO60imFAOykYr9mPKrLRuqHQUQ9O44EJf9Myswf6x7O4QfDYGu-PjPDzy5BuaB5a_o8qCpm_7x0sg=s320" width="320" /></a></div><span style="font-family: arial;"><span style="background-color: white;">
<span style="color: #333333;"><span style="white-space: pre-wrap;"><p>
Spiral is pleased to announce our involvement in another incredibly exciting trial, aimed at producing effective Covid-19 treatments for people in the community, not admitted to hospital.</p></span></span></span></span><p></p><p class="" style="background-color: white; color: #333333; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">Researchers from the <a href="https://www.phc.ox.ac.uk/" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;">Nuffield Department of Primary Care Health Sciences, University of Oxford</a>, have recently announced that they have been awarded funding through the <a href="https://www.nihr.ac.uk/" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;">National Institute for Health Research (NIHR)</a> to work with several UK universities and carry out a first-of-its-kind clinical trial, testing novel antiviral COVID-19 treatments for use early on in the illness by people in the community with COVID-19 who are at higher risk of complications.</span></p><p class="" style="background-color: white; color: #333333; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">Known as <a href="https://www.google.com/url?q=https%3A%2F%2Fwww.nihr.ac.uk%2Fnews%2Fnihr-funds-community-covid-19-antiviral-trial%2F29048&sa=D&source=docs&usg=AOvVaw3P_JTuO5Ccdv_6WK4zXVlQ&ust=1635735859897000" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;" target="_blank">PANORAMIC</a>, this trial is led by <a href="https://www.phc.ox.ac.uk/research/institutes-units/phctrials" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;">Oxford University’s Primary Care Clinical Trials Unit</a>, while the delivery of the trial will be supported by the<a href="https://www.nihr.ac.uk/explore-nihr/support/clinical-research-network.htm" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;"> NIHR Clinical Research Network </a>and devolved administrations. </span></p><p class="" style="background-color: white; color: #333333; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;"><a href="https://www.southampton.ac.uk/medicine/about/staff/psl3.page" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;">Professor Paul Little from the University of Southampton</a> and Co-Chief Investigator has said: </span></p><blockquote style="background-color: white; color: #333333; overflow-wrap: break-word;"><p class="" style="margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;"><b><i>‘This trial will be one of the most ambitious ever undertaken in UK primary care, and will provide vital information about treatments to help the most vulnerable people in the ongoing fight against COVID-19.’</i></b></span></p></blockquote><p class="" style="background-color: white; color: #333333; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;"><a href="https://spiral.co.nz/" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;">Spiral</a> will be supporting this trial with our savvy software platform and our ability to pivot with change. Unlike others, we can adapt our platform for Novel Trials or studies that use unusual design methodologies.</span></p><p class="" style="background-color: white; color: #333333; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">CEO and Founder of Spiral, <a href="https://spiral.co.nz/audrey" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;" target="_blank">Audrey Shearer</a> has said: </span></p><blockquote style="background-color: white; color: #333333; overflow-wrap: break-word;"><p class="" style="margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;"><i><b>"We have a lot of experience with platform trials including the world-renowned REMAP-CAP Trial which is seeking effective Covid-19 treatments for critical care patients. Supporting the team at Oxford University gives us the unique opportunity to help in the search for antiviral treatments that will be effective early on in the disease (PANORAMIC) and in severe cases of the disease (REMAP-CAP). Our sincere hope is that the antiviral treatments included in PANORAMIC will prevent worsening of the disease and stop people from being admitted to hospital."</b></i></span></p></blockquote><p class="" style="background-color: white; color: #333333; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">PANORAMIC also has two sub-studies – the Post Exposure Prophylaxis sub-study will test whether antiviral agents prevent transmission to people living with someone who gets COVID-19; a Virology sub-study aims to find out whether the new treatments reduce viral shedding and if using the new drugs cause the virus to become resistant to treatment.</span></p><p class="" style="background-color: white; color: #333333; margin: 1rem 0px 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">Keep up to date with the Panoramic trial via our <a href="https://spiral.co.nz/panoramic-studyplan" target="_blank">Trial Hub page</a>. We will be updating it as and when more information is made available.</span></p>JessEsshttp://www.blogger.com/profile/01954522457113433993noreply@blogger.com0tag:blogger.com,1999:blog-10743943.post-10794895658503560592021-09-06T11:24:00.001+12:002022-01-19T11:27:15.908+13:00Case Study - PLUS Study and The George Institute for Global Health<p><span style="font-family: arial;"></span></p><div class="separator" style="clear: both; text-align: center;"><span style="font-family: arial;"><a href="https://blogger.googleusercontent.com/img/a/AVvXsEjS-Wj5j1x06SIUyDpoNrLJ2l9lPli1-vyC6wtcz6ftiXEVHan_5to8SbNSOw9zqV3ZZJewHJ72vTj216pmvGps6bXjQFITy419hzlQp3SEVdrdBeeuzj8X0wG-9zOiUCINie9_iM-nxoV6SLmBekoFELsiMRzks776-tBiDFXj_hkvphCs5Q=s1332" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="1332" data-original-width="988" height="320" src="https://blogger.googleusercontent.com/img/a/AVvXsEjS-Wj5j1x06SIUyDpoNrLJ2l9lPli1-vyC6wtcz6ftiXEVHan_5to8SbNSOw9zqV3ZZJewHJ72vTj216pmvGps6bXjQFITy419hzlQp3SEVdrdBeeuzj8X0wG-9zOiUCINie9_iM-nxoV6SLmBekoFELsiMRzks776-tBiDFXj_hkvphCs5Q=s320" width="237" /></a></span></div><span style="font-family: arial;"><br /><span style="background-color: white; color: #333333; font-size: 16px; white-space: pre-wrap;"><br /></span></span><p></p><p><span style="font-family: arial;"><span style="background-color: white; color: #333333; font-size: 16px; white-space: pre-wrap;">When it comes to clinical trials, we look to make a difference around the world with our savvy software platform. We speak to </span><a href="https://www.georgeinstitute.org/people/sharon-micallef" style="background-attachment: initial; background-clip: initial; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; font-size: 16px; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;" target="_blank">Sharon Micallef</a><span style="background-color: white; color: #333333; font-size: 16px; white-space: pre-wrap;">, a Senior Project Manager from </span><a href="https://www.georgeinstitute.org/" style="background-attachment: initial; background-clip: initial; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; font-size: 16px; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;" target="_blank">The George Institute for Global Health</a><span style="background-color: white; color: #333333; font-size: 16px; white-space: pre-wrap;">, about her experience working with the team at Spiral to produce a database for her latest study.</span></span></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; text-align: center; white-space: pre-wrap;"><span style="font-family: arial;">~</span></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">With 20 years of experience behind her as a nurse and an intensive care research coordinator, Sharon Micallef understands the demands and pressures of working within a hospital environment. Now a senior project manager at The George Institute for Global Health, a leading independent medical research institute, she has spent the last ten years working in the Critical Care Division on academically-based studies, drawing on her previous experience to help run trials that will benefit critically ill patients. </span></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">Based in Sydney, her latest study, <a href="https://www.georgeinstitute.org/projects/plasma-lyte-148r-versus-saline-plus-study" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;" target="_blank">PLUS</a> (Plasma-Lyte® Vs Saline) is a multi-centre, blinded, randomised, controlled trial (RCT) which will determine whether fluid resuscitation and intravenous fluid therapy with a “balanced” crystalloid solution (Plasma-Lyte 148®) decreases 90-day mortality in critically ill patients requiring fluid resuscitation when compared with the same treatment using 0.9% sodium chloride (saline).</span></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">Essentially, the study has been comparing two types of intravenous fluids that are used as standard care in ICUs in Australia and New Zealand. There has been an ongoing discussion about the high chloride content in saline and its potential to cause acute kidney injury, but they wanted to know, is Plasma-Lyte safer? Sharon’s study needed to easily and efficiently compare these two standard fluids for patients that require fluid resuscitation in ICUs.</span></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">With over 5,000 patients enrolled across Australia and New Zealand, it was vital to create a study database that was designed in a way that made inputting information on the frontline as easy as possible. Halfway through the initial study database design, Sharon came to the realisation that it was too complicated from a research coordinator’s perspective. </span></p><blockquote style="background-color: white; color: #333333; font-size: 16px; overflow-wrap: break-word;"><p class="" style="margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;"><b><i>“If your research coordinators find it hard to work with the database, it impacts on the study, recruitment, speed of entering data - the flow-on effect is huge”</i></b></span></p></blockquote><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">Knowing that the current format would slow down recruitment, Sharon decided that something needed to change - and fast. Having worked with Spiral before on the <a href="https://www.georgeinstitute.org/projects/permissive-hyperthermia-through-avoidance-of-paracetamol-in-sepsis-trial-heat-study" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;" target="_blank">HEAT</a> study several years ago, Sharon felt that engaging with our team would be the right way to go, even if it meant a setback in the timelines of the study. </span></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">A conversation with the PLUS study <a href="https://www.georgeinstitute.org/people/simon-finfer" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;" target="_blank">Chief Investigator Professor Simon Finfer</a> led to a meeting with our Founder <a href="https://spiral.co.nz/audrey" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;" target="_blank">Audrey</a>, and work got underway almost immediately and - as they say - the rest is history. This change in the database meant an 8-month delay in starting recruitment but Sharon believes it was worth the wait. </span></p><blockquote style="background-color: white; color: #333333; font-size: 16px; overflow-wrap: break-word;"><p class="" style="margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;"><i><b>“I tell everyone it is worth putting that effort in at the beginning. In the end, we haven’t needed the data validation resources other studies require because it was so beautifully done by Spinnaker - I’m very grateful to Audrey and the team - we have a great working relationship”</b></i></span></p></blockquote><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">The bespoke design process was something new to Sharon and she admits being thrown in the deep end. Sharon provided paper forms to work from (randomisation, baseline etc). Our team were then able to design a similar electronic format. </span></p><blockquote style="background-color: white; color: #333333; font-size: 16px; overflow-wrap: break-word;"><p class="" style="margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;"><i><b>“There was a lot of hard work involved but Audrey and the team were extremely patient with me”</b></i></span></p></blockquote><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">With her own personal experience front of mind, Sharon understood the wants and needs of both ICU nurses and research coordinators and was able to translate this to Spiral. It was imperative that the functioning database required very few steps, making the randomisation process as easy as possible for the nursing and medical staff who were physically inputting the information while attending to a critically ill patient. This need underpinned the entire trial. </span></p><blockquote style="background-color: white; color: #333333; font-size: 16px; overflow-wrap: break-word;"><p class="" style="margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;"><i><b>“Throughout the process, I would think to myself: what would I want if I was working at the other end? What would make my work easier?”</b></i></span></p></blockquote><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">While the results of Sharon’s study are still embargoed, she could say that working with Spiral and the use of <a href="https://spiral.co.nz/our-platform" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;" target="_blank">Spinnaker</a> has made the process so much easier. Being able to access reports and blinded data all the way through the study has made things so much more efficient.</span></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">To give some background on this, study databases traditionally work with something of a data management ‘middle man’. Meaning that if a report is needed, it has to be requested through data management, taking a few days to return before anyone can review the data and check for inconsistencies. But with the use of Spinnaker, if Sharon needs a report with specific data, she can simply download a blinded report, filter data, check for inconsistencies and send data queries to sites straight away. Sharon believes the ease with which she is able to access and review everything herself saves so much time. </span></p><blockquote style="background-color: white; color: #333333; font-size: 16px; overflow-wrap: break-word;"><p class="" style="margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;"><i><b>“It is undoubtedly one of the best features.”</b></i></span></p></blockquote><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">When looking to the future of trials, Sharon believes that a good database is absolutely essential. Without one, timelines can stretch out endlessly, making the trial seem impossible to complete. Whilst Sharon has mostly worked on randomised controlled trials, she loves the way that Spiral has been able to embrace platform trials where multiple treatments are tested at the one time.</span></p><p class="" style="background-color: white; color: #333333; font-size: 16px; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">Personally driven by the power of clinical research, Sharon is an advocate for any product that enables researchers to conduct trials more efficiently, which in turn benefits people and patients in the long run. Her inherent need to help people through her study, research and trials is made all that much easier with Spiral. </span></p><blockquote style="background-color: white; color: #333333; font-size: 16px; margin-bottom: 0px; overflow-wrap: break-word;"><p class="" style="margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;"><b><i> “Spiral has been amazing, I have had a great time working with them. They have been very professional and answered all my questions, even the silly ones. I have learnt a lot from Audrey and the team. I would highly recommend them as a company and their product to anyone really. It makes my job a lot easier.”</i></b></span></p></blockquote>JessEsshttp://www.blogger.com/profile/01954522457113433993noreply@blogger.com0tag:blogger.com,1999:blog-10743943.post-46164747701252382482021-08-06T11:16:00.001+12:002022-01-19T11:24:01.988+13:00Full-dose blood thinners benefit moderately ill COVID-19 patients<p><span style="background-color: white; color: #333333; font-family: Poppins; font-size: 16px; white-space: pre-wrap;"></span></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/a/AVvXsEjUQBlglnMdPdLjkm1utmwrgOcZfWQS0X-0xG-3PQNEg8zyOOpfsQZfX4_T2vz0mQz9HJGM3_3g20704G89ed1Ov8x3Z4FCNEj71pwBqJpmltF223ZqXYNrqq1iM35fV1VQhGx8bonJ9pBfNrVvtQ32gzlPPdZghTgD6AIhbrwCx68FwasiKg=s750" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="422" data-original-width="750" height="180" src="https://blogger.googleusercontent.com/img/a/AVvXsEjUQBlglnMdPdLjkm1utmwrgOcZfWQS0X-0xG-3PQNEg8zyOOpfsQZfX4_T2vz0mQz9HJGM3_3g20704G89ed1Ov8x3Z4FCNEj71pwBqJpmltF223ZqXYNrqq1iM35fV1VQhGx8bonJ9pBfNrVvtQ32gzlPPdZghTgD6AIhbrwCx68FwasiKg=s320" width="320" /></a></div>
<p style="text-align: left;"><span style="font-family: arial;"><span style="background-color: white; color: #333333; white-space: pre-wrap;">REMAP-CAP, an application in Spiral’s study manifest, has recently been used in a collaborative clinical trial that focused on identifying effective treatments for critically ill Covid-19 patients.</span><br /><span style="background-color: white; color: #333333; white-space: pre-wrap;">tment options.</span></span></p><p></p><p style="text-align: left;"><span style="background-color: white; color: #333333; white-space: pre-wrap;"><span style="font-family: arial;">Thrombosis was considered to contribute to morbidity and mortality in Covid-19. It was hypothesized that therapeutic anticoagulation would improve outcomes in critically ill patients with Covid-19.</span></span></p><p style="text-align: left;"><span style="background-color: white; color: #333333; white-space: pre-wrap;"><span style="font-family: arial;">An open-label, adaptive, multiplatform, randomized, clinical trial was conducted. Patients with severe Covid-19, defined as the requirement for organ support with high flow nasal cannula, non-invasive ventilation, invasive ventilation, vasopressors, or inotropes, were randomized to receive therapeutic anticoagulation with heparin or pharmacological thromboprophylaxis as per local usual care.</span></span></p><p style="text-align: left;"><span style="background-color: white; color: #333333; white-space: pre-wrap;"><span style="font-family: arial;">Trial data analysis involved 1,074 critically ill and 2,219 moderately ill patients. Physician investigators gauged how long participants were free of organ support up to 21 days after enrolling in the clinical trial. The investigators discovered that in moderately ill patients full-dose heparin reduced the need for organ support compared to those who received lower-dose heparin. By contrast, for critically ill patients, full-dose heparin was associated with a high probability of a worse outcome.</span></span></p><p style="text-align: left;"><span style="background-color: white; color: #333333; white-space: pre-wrap;"><span style="font-family: arial;">The worldwide multi-platform trial spanned five continents in over 300 hospitals to urgently test blood thinners on both sets of patients, the critically and non-critically ill.</span></span></p><p style="text-align: left;"><span style="background-color: white; color: #333333; white-space: pre-wrap;"><span style="font-family: arial;">The results have shown that full-dose anticoagulation with the blood thinner heparin improves survival outcomes and reduces the need for vital organ support such as mechanical ventilation in moderately ill COVID-19 patients, but does not yield the same positive outcomes among critically ill patients already requiring life support.</span></span></p><p style="text-align: left;"><span style="background-color: white; color: #333333; white-space: pre-wrap;"><span style="font-family: arial;">As summarised by Professor Steve Webb, director of REMAP-CAP: <i>“Our conclusions have set a new, accessible and affordable standard of care for moderately ill hospitalised COVID-19 patients around the world using a familiar drug. As such the results of the trial can be immediately applied,”</i></span></span></p><p style="text-align: left;"><span style="background-color: white; color: #333333; white-space: pre-wrap;"><span style="font-family: arial;">These results come at a crucial time when Australia is dealing with outbreaks in several states, therefore there is renewed interest in treatment options.<br /></span></span></p><p style="text-align: left;"><span style="background-color: white; color: #333333; white-space: pre-wrap;"><span style="font-family: arial;">Spiral is proud to be a part of this worldwide multi-platform trial, one that spanned five continents in over 300 hospitals, helping to urgently test blood thinners on both sets of patients who were ill or critically ill with Covid-19.</span></span></p><div class="blog-item-content e-content" style="background-color: white; color: #333333; margin: 0px 0px 3vw;"><div class="sqs-layout sqs-grid-12 columns-12" data-layout-label="Post Body" data-type="item" id="item-610c9185b2150352fbf6ea8f"><div class="row sqs-row" style="margin-left: -17px; margin-right: -17px; width: auto !important;"><div class="col sqs-col-12 span-12" style="float: left; padding-right: 0px; width: 898px;"><div class="sqs-block html-block sqs-block-html" data-block-type="2" id="block-b2c633fc1a87fa74b8b7" style="clear: none; height: auto; padding: 0px 17px 17px; position: relative;"><div class="sqs-block-content" style="outline: none;"><p class="" style="margin: 1rem 0px; overflow-wrap: break-word; text-align: left; white-space: pre-wrap;"><span style="font-family: arial;">Dive deeper:</span></p><ul data-rte-list="default" style="overflow-wrap: break-word; text-align: left;"><li style="list-style-type: none; overflow-wrap: break-word;"><p class="" style="margin: 0.5em 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;"><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2105911" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;">The New England Journal of Medicine Publication</a> </span></p></li><li style="list-style-type: none; overflow-wrap: break-word;"><p class="" style="margin: 0.5em 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">Trial Results Meeting Online at <a href="https://criticalcarereviews.com/" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;"><span style="overflow-wrap: break-word;">Critical Care Reviews</span></a></span></p></li><li style="list-style-type: none; overflow-wrap: break-word;"><p class="" style="margin: 0.5em 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">The Medrxiv <a href="https://www.medrxiv.org/content/10.1101/2021.03.10.21252749v1" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;">website</a></span></p></li></ul><p class="" style="margin: 1rem 0px 0px; overflow-wrap: break-word; text-align: left; white-space: pre-wrap;"><span style="font-family: arial;">The REMAP-CAP <a href="https://ttm2trial.org/" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;"><span style="overflow-wrap: break-word;">Website</span></a></span></p><div style="font-family: Poppins; font-size: 16px;"><br /></div></div></div></div></div></div></div>JessEsshttp://www.blogger.com/profile/01954522457113433993noreply@blogger.com0tag:blogger.com,1999:blog-10743943.post-71490966019717619342021-08-05T11:10:00.001+12:002022-01-19T11:15:14.930+13:00Meet Emma - One of our Project Managers at Spiral<p><span style="background-color: white; color: #333333; font-family: Poppins; font-size: 16px; white-space: pre-wrap;"></span></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/a/AVvXsEjNuAxefEhAJ7j4K4UAjCs7Hhd4EQFGHQ6CeWyiUH8qJWsc_Dlb1G1yMs6kP4r9-dsm0Nhe0O8KoM0IVzyp31KZug9VYnboNY6AqUpRI0nZ3JG1Y6bmv_fAMDS8AqT9QTQA0DltqmK7uSGDIcLqipWnughgAxSoyvIJOKYA4q4sBjFgMqB1OQ=s750" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><span style="font-family: arial;"><img border="0" data-original-height="750" data-original-width="750" height="320" src="https://blogger.googleusercontent.com/img/a/AVvXsEjNuAxefEhAJ7j4K4UAjCs7Hhd4EQFGHQ6CeWyiUH8qJWsc_Dlb1G1yMs6kP4r9-dsm0Nhe0O8KoM0IVzyp31KZug9VYnboNY6AqUpRI0nZ3JG1Y6bmv_fAMDS8AqT9QTQA0DltqmK7uSGDIcLqipWnughgAxSoyvIJOKYA4q4sBjFgMqB1OQ=s320" width="320" /></span></a></div><span style="font-family: arial;"><br /></span><div class="separator" style="clear: both; text-align: center;"><span style="font-family: arial;"><br /></span></div><span style="font-family: arial;"><br />Meet Emma. As a Project Manager, Emma wears many hats here at Spiral. Her main role is to oversee the software development used in clinical trials all around the world, but on any given day you can find her jumping from testing to managing sprints, answering support tickets, developing wireframes or liaising with clients on Zoom.</span><p></p><p class="" style="background-color: white; color: #333333; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><strong style="overflow-wrap: break-word;"><em style="overflow-wrap: break-word;"><span style="font-family: arial;"> “It is an incredibly agile environment. Whatever comes my way - I jump on it and deal with it”</span></em></strong></p><p class="" style="background-color: white; color: #333333; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">When Emma left school, she thought a career in tourism would be her calling. She completed her degree but a casual job at a pet store led to seven years as a vet nurse. As an animal lover, it was the space Emma thought she would be in for the rest of her career but she found that some aspects of the job took a huge emotional toll on her. </span></p><p class="" style="background-color: white; color: #333333; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">Deciding it was time to leave this role behind, her career went down a different path as she took the plunge into IT. Having no previous experience she managed to get her foot in the door of a large corporation. Emma found she excelled within this industry - it even took her to Silicon Valley where she and her husband worked within a Kiwi-owned IT company. </span></p><p class="" style="background-color: white; color: #333333; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">Upon her return to New Zealand, Emma took up a senior role at an HR Technology SaaS company. This role lasted for six years until Covid struck, causing her job to be made redundant. Despite this, Emma enjoyed success with several contract roles following her redundancy. When looking for the next step in her career, she came across an advert for a Project Manager at Spiral and couldn't believe what she was reading. The company was doing things she could be passionate about and be rewarded in facilitating.</span></p><p class="" style="background-color: white; color: #333333; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><strong style="overflow-wrap: break-word;"><em style="overflow-wrap: break-word;"><span style="font-family: arial;">“I thought, what is the catch? This is too good to be true”</span></em></strong></p><p class="" style="background-color: white; color: #333333; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">Now living in Tauranga and working remotely for Spiral, Emma wonders why she hadn’t got into this space earlier. She loves the flexibility of working remotely with the support of her colleagues. She compares it to her past experience in open-plan offices where it was easy to get interrupted or feel like she could never fully complete a job to her satisfaction.</span></p><p class="" style="background-color: white; color: #333333; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><strong style="overflow-wrap: break-word;"><em style="overflow-wrap: break-word;"><span style="font-family: arial;">“I love working from home. Corporates that are trying to maintain the traditional office environment haven’t given remote working much of a chance to see how well their employees can perform.”</span></em></strong></p><p class="" style="background-color: white; color: #333333; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">Looking back Emma realises just how valuable her experience has been to get her to where she is today. Two very unlikely industries have collided to provide her with the skill sets that she uses every single day at Spiral. She owes her medical knowledge, understanding of the jargon, and even pronunciation of certain medicines to her vet nurse experience. On the other hand, her years within the IT industry have given her the valuable background to oversee the software development at Spiral. </span></p><p class="" style="background-color: white; color: #333333; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><strong style="overflow-wrap: break-word;"><em style="overflow-wrap: break-word;"><span style="font-family: arial;">“My job history has come together and manifested in a role that I never knew was possible.” </span></em></strong></p><p class="" style="background-color: white; color: #333333; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">When reflecting on the challenges of the role, Emma admits there are stressors involved. The juggling can be difficult at times but that is part and parcel of working in an agile environment and with so many people putting their hands up for trials, she feels the need to help everyone. </span></p><p class="" style="background-color: white; color: #333333; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">The pressure to get it right can be immense. Emma and the team are dealing with sensitive issues every day while liaising with staff in hospitals who are on the frontline of the pandemic. But despite this, she can wake up each day knowing that she is doing something meaningful with Spiral, that her job has a purpose and is making a difference in the current world we’re living in. </span></p><p class="" style="background-color: white; color: #333333; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><strong style="overflow-wrap: break-word;"><em style="overflow-wrap: break-word;"><span style="font-family: arial;">“It is easy to get caught up in the emotions of this role but at the same time, it is incredibly rewarding.”</span></em></strong></p><p class="" style="background-color: white; color: #333333; margin: 1rem 0px; overflow-wrap: break-word; white-space: pre-wrap;"><span style="font-family: arial;">With her one-year anniversary at Spiral just around the corner, Emma feels like she has found herself a role where she can support others to be the best they can be while at the same time, work within a team that ‘keeps it real’ and bands together.</span></p><p class="" style="background-color: white; color: #333333; margin: 1rem 0px 0px; overflow-wrap: break-word; white-space: pre-wrap;"><strong style="overflow-wrap: break-word;"><em style="overflow-wrap: break-word;"><span style="font-family: arial;">“This really is the dream job. The team spirit and support is amazing- everyone is so genuine and kind - I feel like I've finally found the right role for me and my long term career. I can't imagine doing anything else now.”</span></em></strong></p>JessEsshttp://www.blogger.com/profile/01954522457113433993noreply@blogger.com0tag:blogger.com,1999:blog-10743943.post-32228272848130775912021-06-29T17:09:00.004+12:002021-06-29T17:09:59.256+12:00TTM2 Trial: Hypothermia vs. Normothermia after Out-of-Hospital Cardiac Arrest<p><span style="background-color: white;"></span></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgoQKFtkj7jmuq5x69Gf6TWlF2HPz_JsDn2-L8vfoRfKffll8l-lQFvZBV9Z4i0K77d7FkVDvKb_sRo9zAc7GroAHNLSBtsy1TRj9DZZmy9LOMa7aE8p_aRm4zySC8Te3Bg3yp1/s500/irwan-iwe-QTiGyY47Si0-unsplash.jpeg" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="375" data-original-width="500" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgoQKFtkj7jmuq5x69Gf6TWlF2HPz_JsDn2-L8vfoRfKffll8l-lQFvZBV9Z4i0K77d7FkVDvKb_sRo9zAc7GroAHNLSBtsy1TRj9DZZmy9LOMa7aE8p_aRm4zySC8Te3Bg3yp1/s16000/irwan-iwe-QTiGyY47Si0-unsplash.jpeg" /></a></div><br />A project <span style="background-color: white; color: #333333; font-family: Poppins; font-size: 16px; white-space: pre-wrap;">in Spiral’s study manifest, has recently been used in the long-awaited </span><a href="https://ttm2trial.org/" style="background-attachment: initial; background-clip: initial; background-color: white; background-image: unset; background-origin: initial; background-position: unset; background-repeat: unset; background-size: unset; color: #f78f5e; cursor: pointer; font-family: Poppins; font-size: 16px; overflow-wrap: break-word; text-decoration-color: currentcolor; text-decoration-skip-ink: auto; text-decoration-style: solid; text-decoration-thickness: 1px; text-underline-offset: 0.2em; white-space: initial;">TTM2</a><span style="background-color: white; color: #333333; font-family: Poppins; font-size: 16px; white-space: pre-wrap;"> trial. After successful resuscitation, patients who survive a cardiac arrest often remain severely ill and require intensive care. Controlling body temperature is a potential treatment that may prevent brain damage. The <a href="https://spiral.co.nz/blog/ttm2-trial-hypothermia-vs-normothermia-after-out-of-hospital-cardiac-arrest" target="_blank">TTM2-trial</a> aimed to study the impact on all-cause mortality of targeted hypothermia compared with targeted normothermia.</span><div><p></p><p><span style="background-color: white; color: #333333; font-family: Poppins; font-size: 16px; white-space: pre-wrap;"><a href="https://spiral.co.nz/blog/ttm2-trial-hypothermia-vs-normothermia-after-out-of-hospital-cardiac-arrest" target="_blank">Read more about this practice changing trial over on our blog</a> »</span></p></div>Audreyhttp://www.blogger.com/profile/10419461620219923125noreply@blogger.com0tag:blogger.com,1999:blog-10743943.post-36882707965788624512021-05-31T10:15:00.002+12:002021-05-31T10:15:55.894+12:00Meet Jess, one of our Project Leads<div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjqvAOgMT2Gvr0t0iqUfuyMzGkGk8LOYrTXeB8NMskuC4rXs_alN6yA7THsXPsg9fgojhNM1_D1WxGvYMtrw6LqYH-9ObkHa3GR2sRgXpwIxWYjNZcKQfzM__DYHyiM3a9gqmd6/s250/Jess+clipped.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="250" data-original-width="250" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjqvAOgMT2Gvr0t0iqUfuyMzGkGk8LOYrTXeB8NMskuC4rXs_alN6yA7THsXPsg9fgojhNM1_D1WxGvYMtrw6LqYH-9ObkHa3GR2sRgXpwIxWYjNZcKQfzM__DYHyiM3a9gqmd6/s0/Jess+clipped.png" /></a></div><br /><div><br /></div>Ask her what a typical day or week looks like and Jess can’t help but laugh. <div><br /></div><div><i> “Every day is different and every week throws up new challenges. I find myself to be very busy. The pressures of the pandemic are immense and with the trial being responsive, the build constantly needs to change...you hear of working in an agile environment but this really is as agile as it gets.” </i><div><br /></div><div><a href="https://spiral.co.nz/blog/meet-jess-wren" target="_blank">Read more about Jess over on our blog</a> »</div></div>Audreyhttp://www.blogger.com/profile/10419461620219923125noreply@blogger.com0tag:blogger.com,1999:blog-10743943.post-41897752623890510062021-03-29T13:49:00.006+13:002021-03-29T13:49:48.258+13:00Spiral donates Chromebooks to help UK students during COVID-19 lockdowns<div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiCHsiNrOw6rIMyNCPnWlF-U28mgma8_RXfj9yceKVSt80wS4wuc2wiHVuTkQq66nWl4M8S-jCSPXQsOeea9woCmWqKrZtKhEeMf1V6jwKTw-NPLComE-chGbAwwpTe6UBQjGKE/s797/Grange+Chromebooks+2.png" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" data-original-height="797" data-original-width="479" height="400" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiCHsiNrOw6rIMyNCPnWlF-U28mgma8_RXfj9yceKVSt80wS4wuc2wiHVuTkQq66nWl4M8S-jCSPXQsOeea9woCmWqKrZtKhEeMf1V6jwKTw-NPLComE-chGbAwwpTe6UBQjGKE/w240-h400/Grange+Chromebooks+2.png" width="240" /></a></div><div class="separator">It’s been over a year since COVID-19 struck the world, and at Spiral we continue to think about the impact it has on our most vulnerable people – and not just in a clinical context. </div><div><div><br /></div><div>With many schools around the world in lockdown, students are expected to learn from home with online lessons. But what happens when a family doesn’t have a device? Or just one device to share between children? </div><div><br /></div><div>With this in mind, Spiral recently donated four new HP Chromebooks to Grange First Primary School in the UK. They’re a low decile school in one of the more economically challenged parts of London, and while the government had provided some Chromebooks to assist at-home learning, they were still short. That meant children were having to join lessons from their parent’s phone, or in families with more than one sibling, share devices. This often meant that one or more siblings simply didn’t get to do lessons that day. </div><div><br /></div><div><a href="https://spiral.co.nz/grange-chromebook-donation" target="_blank">Read more about the chromebooks and watch the video</a> »</div><div><br /></div><div><br /><br /></div><div><br /></div></div>Audreyhttp://www.blogger.com/profile/10419461620219923125noreply@blogger.com0tag:blogger.com,1999:blog-10743943.post-76151648323096463812021-02-23T12:21:00.000+13:002021-02-23T12:21:20.795+13:00Stew Duff, who makes what we do at Spiral technically possible<p><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEikMccXOD5C6yc6QAbhli3O9LR8lfM2lKZDhAj-fkdhkwib0jWOOdSqIAJt5_LbM8qJa3LQhh5tfvLnylk_fRglU_CNFrS5yJGqf5rfqhIjIkR7AJ9V55wIiDEl7TfUleYJj0fS/s720/Stew+in+Cottage.png" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="693" data-original-width="720" height="616" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEikMccXOD5C6yc6QAbhli3O9LR8lfM2lKZDhAj-fkdhkwib0jWOOdSqIAJt5_LbM8qJa3LQhh5tfvLnylk_fRglU_CNFrS5yJGqf5rfqhIjIkR7AJ9V55wIiDEl7TfUleYJj0fS/w640-h616/Stew+in+Cottage.png" width="640" /></a></p>
<p> He’s not a researcher signing up patients for life-saving clinical trials – but he does determine eligibility.</p><p>He’s not a doctor, or a nurse, seeing patients and delivering recovery results – but he does do patient follow-ups and reporting. </p><p>He’s not on the front-lines, but he is helping to save lives from the back end.</p><p> <a href="https://spiral.co.nz/meet-stew-one-of-our-developers/" target="_blank" style="text-decoration: underline;">Meet Stew, one of our Developers</a> »</p>Audreyhttp://www.blogger.com/profile/10419461620219923125noreply@blogger.com0tag:blogger.com,1999:blog-10743943.post-1008612281244479642021-02-10T12:54:00.000+13:002021-02-10T12:54:09.504+13:00Application barnacle scraping<p></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjQz2iNpANZauxdP_jCbjtZ3nNOKE7Iw8yXqk88gI0jBbrAUksjArSBHx7pYgWnh10K8evjEPpWnJStxWRz0YeRFKdHTgedQEb6Y3Iunmkt-pfEUrS27gRK_jTfLQwz_yRt0nRp/s640/Barnacle+Scraping+3.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="330" data-original-width="640" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjQz2iNpANZauxdP_jCbjtZ3nNOKE7Iw8yXqk88gI0jBbrAUksjArSBHx7pYgWnh10K8evjEPpWnJStxWRz0YeRFKdHTgedQEb6Y3Iunmkt-pfEUrS27gRK_jTfLQwz_yRt0nRp/s16000/Barnacle+Scraping+3.png" /></a></div><br />Our developers have been engaged in "barnacle scraping" this week. <p></p><p><br />Like the hull of a ship, software needs to go through periodic barnacle scraping, especially when we are making lots of changes and adaptations. Adapting our software platform for COVID research studies has pretty much become the norm for us. All those adaptations leave "barnacles" or little extras which are extraneous to the functioning of the platform and can slow things down. <br /><br />We can do all this while the software application continues to run so carry on as usual. The changes we have been making will improve performance, speed up response times and make things smoother for you. <br /><br />Thank you for your comments and feedback. </p><p> </p>Audreyhttp://www.blogger.com/profile/10419461620219923125noreply@blogger.com0tag:blogger.com,1999:blog-10743943.post-8327919861379685282021-01-01T06:00:00.001+13:002021-01-01T06:00:08.086+13:00Happy New Year 2021<p> </p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiIRq691bV_6_nX-9Lux-Kq4PFHqp3QuWpArPcI38VuymBydXnSEMeQloWxPXMxPGBduQ_-wRH2OmK9gpmYc0jPNLSuUWP0BL2MtfmnME0-zGNfdG5B_Z-agCQB6yR4X4JU9LuR/s936/Happy+New+Year+2021.png" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="478" data-original-width="936" height="327" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiIRq691bV_6_nX-9Lux-Kq4PFHqp3QuWpArPcI38VuymBydXnSEMeQloWxPXMxPGBduQ_-wRH2OmK9gpmYc0jPNLSuUWP0BL2MtfmnME0-zGNfdG5B_Z-agCQB6yR4X4JU9LuR/w640-h327/Happy+New+Year+2021.png" width="640" /></a></div><p><br /></p>This past year has been one for the record books! We just want to say how grateful we are for your support and we’re wishing you all the best as we enter a brand new year.<p></p><p><a href="https://spiral.co.nz/blog" target="_blank">Head on over to our blog to find out what we are up to</a> »</p>Audreyhttp://www.blogger.com/profile/10419461620219923125noreply@blogger.com0tag:blogger.com,1999:blog-10743943.post-64346157378678363352020-12-22T16:11:00.005+13:002020-12-22T16:20:47.406+13:002020 Recap & Merry Xmas <div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjXRxLx3s7QY6e07TC6IuX2wFxmrESr1SfZhvhomE0QlusBCtMWRq05KLMBQOMkardbcv0bd9Ec4ZpDL_Bztb7IbdQsvqYcIm-NtfP_hHD9P7f4bwkDuzuq7KNG9y3rdzbX_wVD/s1800/Team2020+XmaswithLogo.png" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="300" data-original-width="1800" height="106" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjXRxLx3s7QY6e07TC6IuX2wFxmrESr1SfZhvhomE0QlusBCtMWRq05KLMBQOMkardbcv0bd9Ec4ZpDL_Bztb7IbdQsvqYcIm-NtfP_hHD9P7f4bwkDuzuq7KNG9y3rdzbX_wVD/w640-h106/Team2020+XmaswithLogo.png" width="640" /></a></div><br />
2020 was a year of challenges, to say the least
Covid-19 brought immense challenges to everyone in 2020, and it brought us our greatest challenge ever: adapting our Spinnaker platform to manage the world’s most complex clinical trial – a trial that tackled Covid-19 head-on.
<br /><br />
<h3>A recap of REMAP-CAP: the clinical trial fighting Covid-19</h3>
As we speak the REMAP-CAP trial has over 3,500 patients enrolled, in over 15 countries, at 300 sites around the world. And during the year, our software randomised over 5,200 patients – go you awesome researchers!
I want to take a moment to reflect on the real human impact. It’s easy to get caught up in technical details and statistics, but at the bottom line, the goal of the REMAP-CAP trial, and the Spinnaker platform, is to try and help real people who are sick – in some cases very sick – have a higher probability of receiving a treatment that will help. We feel proud to have been a part of a study with real-world, immediate impact.
<br /><br /><h3>REMAP-CAP milestones </h3><p>
By February, we were already in the thick of <u><a href="https://spiral.co.nz/coronavirus-and-how-we-play-the-adaptation-game/">adapting our Spinnaker platform to tackle Covid-19</a></u>.
It’s strange to look back to this article in <u><a href="https://www.stuff.co.nz/business/better-business/120669574/kiwi-technology-firms-are-at-the-frontline-in-the-global-battle-against-the-coronavirus">Stuff in March</a></u> about our work and read that we had just 50 Covid-19 patients enrolled in the clinical trial to investigate the best treatments.
By April, our sprint out of the blocks had become a long-distance run, and we settled in for a marathon effort. Even now, in December, as we prepare data for analysis that will hopefully answer questions about COVID-19 treatment in critically ill patients, the finish line seems far away.
But this year hasn’t all been about REMAP-CAP! Here’s a look at some of the other studies we’re excited to be a part of.<br /><br /></p><h3><u><a href="https://spiral.co.nz/updates-on-studies-using-spinnaker-dec-2020/">Updates on studies using Spinnaker</a></u> »<br /><br /></h3>
<h3 style="text-align: left;">News about the Spiral team – we’re growing, fast</h3>
An increased demand for our services has resulted in a doubling of the team at Spiral, and we’re so happy to have the new hands on deck for what looks like a busy year ahead.
During the year, new team members Jess, Emma and Stew all worked on delivering our Spinnaker trial platform along with Cain, Craig and Anna. Jess also delivered... a new baby!
The team at Spiral are distributed across New Zealand, and everyone was able to work from home during our lockdown. The only significant effect of the New Zealand lockdowns was to give us more hours in which to work! But it’s not all work for the team and in August, with travel restrictions lifted, we were able to meet up in Wellington for a few days of eating, working and having fun together.
<br /><br /><h3>Community Support</h3>
We are grateful for the organisations the help make our communities better places and we showed our appreciation by supporting:
<ul>
<li>Innovative Young Minds. A nation-wide programme encouraging young women in STEMM careers.</li>
<li>Books in Homes, Xmas Parcels and Reading Assistance in local schools</li>
<li>Wikipedia Foundation.</li>
<li>Wellington Free Ambulance.<br /><br /></li>
</ul>
<p style="text-align: left;"><em>Take care and enjoy this time with your friends and loved ones.</em>
<em>Nga kirihimete, god Jul, Merry Christmas,</em>
<em>from Audrey and all the team at Spiral</em></p>Audreyhttp://www.blogger.com/profile/10419461620219923125noreply@blogger.com0tag:blogger.com,1999:blog-10743943.post-65550962173391876762020-11-24T11:11:00.000+13:002020-11-24T11:11:10.743+13:00The medical world has really stepped up in terms of collaboration during this pandemic, because we can work faster when we work together<p><b>The Result:</b> Arthritis drug found effective in treating sickest COVID-19 intensive care patients.</p><p>November 2020.</p><p><a href="https://spiral.co.nz/remap-cap-update-nov-2020" target="_blank">Read more</a> »</p><p></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgwyD93h1-Jc8_8Ks0y_pqYEjI46_S9YvLPQhBnPDa7tcpGTIW1O-pvcsuPbxlL_6-kKuFtobrd1AqjA2lxlEnkW7cxoQuhZssKpLMEBDFE918tIXvBa6nL-tBWZ8YQc216VM2Z/" style="margin-left: 1em; margin-right: 1em;"><img alt="Spiral Team 2020" data-original-height="959" data-original-width="1847" height="332" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgwyD93h1-Jc8_8Ks0y_pqYEjI46_S9YvLPQhBnPDa7tcpGTIW1O-pvcsuPbxlL_6-kKuFtobrd1AqjA2lxlEnkW7cxoQuhZssKpLMEBDFE918tIXvBa6nL-tBWZ8YQc216VM2Z/w640-h332/image.png" title="Spiral Team 2020" width="640" /></a></div><br /><br /><p></p>Audreyhttp://www.blogger.com/profile/10419461620219923125noreply@blogger.com0tag:blogger.com,1999:blog-10743943.post-9291567274739785652020-09-11T08:54:00.000+12:002020-09-11T08:54:38.577+12:00Meet Jess and Emma our Project Managers<p> </p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjZs-BYiSuvgf6k2S9p238yU5z4oiqTRr9KH7KViLxdZMbpDadq8fiCjiFyrl14dPvPvjSyvW7hC-ZnRXDbo54J-VvLlwJhyphenhyphen9qy97yLyPkyI28B0NaT8k0B5egE2Pgr2elwmLA1/s700/0_egZiosZCaPfFY3km.jpg" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="466" data-original-width="700" height="266" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjZs-BYiSuvgf6k2S9p238yU5z4oiqTRr9KH7KViLxdZMbpDadq8fiCjiFyrl14dPvPvjSyvW7hC-ZnRXDbo54J-VvLlwJhyphenhyphen9qy97yLyPkyI28B0NaT8k0B5egE2Pgr2elwmLA1/w400-h266/0_egZiosZCaPfFY3km.jpg" width="400" /></a></div><br /><br />Two smart, focussed project managers have joined Spiral recently. It’s very nice to have extra hands on deck to help deliver our Covid-19 projects.<br /><br />Meet Jess and Emma our Project Managers for REMAP-CAP and for ASCOT-ADAPT. You can <a href="https://spiral.co.nz/growing-team/" target="_blank">read more about them over on our blog</a> »<p></p>Audreyhttp://www.blogger.com/profile/10419461620219923125noreply@blogger.com0tag:blogger.com,1999:blog-10743943.post-67576869587804620602020-02-20T14:18:00.002+13:002020-02-20T14:18:31.688+13:00Coronavirus and how we play the adaptation game<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiSt_p8veb2o2uZnOK1TTHjq_zyk1UlyLb6f10EmaxOw2wXY6XK3vXJejz9h1yyfxIfNQs58krBlVG7xkFjOZI1s9xFQjbvjegIkiAfayKHo2Ei2gMOaJOK08L667ww6gOiXtTz/s1600/1024px-SARS-CoV-2.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="1025" data-original-width="1024" height="320" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiSt_p8veb2o2uZnOK1TTHjq_zyk1UlyLb6f10EmaxOw2wXY6XK3vXJejz9h1yyfxIfNQs58krBlVG7xkFjOZI1s9xFQjbvjegIkiAfayKHo2Ei2gMOaJOK08L667ww6gOiXtTz/s320/1024px-SARS-CoV-2.png" width="319" /></a></div>
<div style="background-color: white; box-sizing: border-box; color: #747474; font-family: "Open Sans"; font-size: 18px; margin-bottom: 20px;">
We are busy adapting one of our biggest projects to collect data and eventually provide feedback on the best treatment for the novel coronavirus outbreak COVID-19.</div>
<div style="background-color: white; box-sizing: border-box; color: #747474; font-family: "Open Sans"; font-size: 18px; margin-bottom: 20px;">
Coronavirus mutated( or adapted) recently to give us SARS-CoV-2 and the COVID-19 disease. Adaptation is a great skill for a virus – it's a pretty keen skill for people too, and we are using it to fight back against this disease ... <a href="https://spiral.co.nz/coronavirus-and-how-we-play-the-adaptation-game/" target="_blank">read how</a> »</div>
<br />Audreyhttp://www.blogger.com/profile/10419461620219923125noreply@blogger.com0tag:blogger.com,1999:blog-10743943.post-34772115432582456972020-02-11T12:56:00.001+13:002020-02-11T12:57:23.529+13:00The largest ever cardiac arrest trial performed in an ICU setting uses Spinnaker in novel ways!<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEilzaGsls4sMk2S6dGm4LrE0aWe0mk1lkzTT5MMNqfrsk4-eXgaL0o90orLMVarVs7O1GR8sEdVJKrzg26tplt_nTjNBrFYJYsX0GrI8Cz7iAa3mycrYkJVpZrNBZzBupOiiZdC/s1600/Ice-Heart-600x375.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="375" data-original-width="600" height="400" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEilzaGsls4sMk2S6dGm4LrE0aWe0mk1lkzTT5MMNqfrsk4-eXgaL0o90orLMVarVs7O1GR8sEdVJKrzg26tplt_nTjNBrFYJYsX0GrI8Cz7iAa3mycrYkJVpZrNBZzBupOiiZdC/s640/Ice-Heart-600x375.jpg" width="640" /></a></div>
January 2020 saw the last patient enrolled in the TTM2 Trial. Congratulations TTM2 – the largest ever cardiac arrest trial performed in an ICU setting!<br />
The trial has been using our Spinnaker Platform in a novel way, which is what this post is about!<br />
<br />
Back in 2017 we were approached by Principle Investigator, Niklas Nielsen, looking for a way to streamline the collection of data for TTM2 and a similar study, TAME. The 2 studies had very similar data points to collect and there seemed to be an opportunity to save time by collecting data just once and sharing it across both studies. Very quickly it got more complicated than that. Patients could be randomised to TTM2, or TAME, or to participate in both studies. The big question was – could the Spinnaker Platform be adapted to this novel design?<br />
<br />
We are very proud of our adaptability so we had a close look at what we could do ... <a href="https://spiral.co.nz/the-largest-ever-cardiac-arrest-trial-performed-in-an-icu-setting-uses-spinnaker-in-novel-ways/" target="_blank">follow the story on our blog</a> »Audreyhttp://www.blogger.com/profile/10419461620219923125noreply@blogger.com0